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YHTEENVETO 
Eturauhaskoepalat ovat patologin kannalta yksi yleisimmistä näytteistä, joissa 
diagnosoidaan syöpä. Väitöskirjatyön tarkoituksena oli tutkia eturauhassyöpään 
johtavia mekanismeja sekä löytää uusia diagnostisia menetelmiä ja ennustetekijöitä.   
Eturauhassyöpä on arkkitehtuuriltaan vaihteleva ja yleensä multifokaalinen eli 
monipesäkkeinen kasvain, jossa eri kasvainfokukset saattavat syntyä toisistaan 
riippumatta de novo. Ensimmäisessä osatyössä tutkittiin ohjelmoituun 
solukuolemaan eli apoptoosiin osallistuvien biologisten merkkiaineiden BAX ja 
BCL-2 ilmentymistä potilaskohtaisesti valmistetuissa kudossiruissa, joihin oli 
valittu eturauhasen normaaleita alueita, liikakasvua, syöpää ja sen esiasteita. BAX:n 
ilmentyminen oli vähäisintä histologisesti hyvänlaatuisilla alueilla lisääntyen 
tasaisesti aggressiivista syöpää kohden, ja oli huipussaan alueilla, joissa syöpää 
tavattiin hermojen ympärillä. BCL-2:n ilmentyminen oli kaksihuippuinen, toinen 
huippu havaittiin syövän esiasteissa (PIN) ja toinen huonosti erilaistuneessa 
karsinoomassa. Tulokset viittaavat siihen, että apoptoosin säätely kytkeytyy tiiviisti 
syövän etenemiseen. Uusi havainto oli, että molempia proteiineja ilmentyi myös 
jonkin verran syöpää sisältävien eturauhasten mikroskooppisesti normaaleilla 
alueilla, toisin kuin kokonaan hyvänlaatuisissa eturauhasissa. Löydös viittaa 
kenttävaikutukseen, joka voi olla eturauhassyövän monipesäkkeisyyden taustalla. 
Suomessa todetaan vuosittain 4000 - 5000 uutta eturauhassyöpää, joista suuri osa 
löytyy oireettomilta miehiltä PSA-testauksen perusteella. Siksi eturauhassyövät ovat 
nykyään usein pieniä ja hyvin erilaistuneita, joka samanaikaisesti lisääntyneiden 
näytemäärien kanssa tekee koepalojen histopatologisesta tulkinnasta haasteellista. 
Toisaalta eturauhasessa tavataan pääasiassa vain yhtä kasvaintyyppiä, 
adenokarsinoomaa, joka mahdollistaa rutiininomaisesti tehtävien 
immunohistokemiallisten värjäysten käyttämisen diagnostiikan apuvälineenä. 
Tutkimme 200 Pirkanmaan sairaanhoitopiin alueella eturauhaskoepaloissa käyneen 
potilaan välileikkeistä rutiinisti tehtävän kaksoisimmunovärjäyksen vaikutusta 
diagnostiikan sensitiivisyyteen ja patologin ajankäyttöön.  Kaksoisvärjäyksessä 
neoplastiseen solukkoon sitoutuva AMACR-vasta-aine visualisoitiin sinisellä 
kromogeenillä ja tyvisoluvasta-aineet p63 ja CK-HMW ruskealla. Tutkimuksessa 
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todettiin, että rutiinisti tehtävällä kaksoisvärjäyksellä löytyy enemmän 
syöpäfokuksia kuin nykyisellä käytännöllä, jossa lisävärjäyksiä pyydetään vain 
osassa tapauksista patologin harkinnan mukaan. Valtaosa (75%) kaksoisvärjäyksen 
avulla löytyneistä uusista syöpätapauksista oli hyvin erilaistuneita, mutta osa (25%) 
oli huonosti erilaistuneita. Tulosten perusteella näyttää siltä, että rutiinisti tehtävä 
kaksoisvärjäys parantaa diagnostiikan herkkyyttä ja nopeuttaa patologin 
työskentelyä. Pienten fokusten suhteen on kuitenkin syytä muistaa, että varman 
syöpädiagnoosin tarkkaa alarajaa ei ole määritelty. 
Sen lisäksi, että eturauhassyövät ovat muuttuneet, on koepalojen Gleason-
luokitus uudistettu vuonna 2005. Tutkimme 247 primaaristi hormonihoidetun 
potilaan koepaloista uudistetun Gleason-luokituksen ja muiden histopatologisten 
suureiden ennustearvoa. Kuvannetut näytelasit tutkittiin web-pohjaisella 
virtuaalimikroskoopilla. Totesimme, että uudistettu Gleason-luokitus on vahvimpia 
ennustetekijöitä myös primaaristi hormonihoidetuilla potilailla. Sekä pahin 
koepalakohtainen Gleason-summa että yhdistetty Gleason-summa olivat yhtä hyviä 
ennustamaan taudin uusiutumista. Lisäksi todettiin uusien suositusten johtavan 
Gleason-summien yleiseen nousuun ja Gleason-summan 4+3=7 tai yli osoittavan 
huonontunutta ennustetta. Entuudestaan tiedetään, että eturauhassyöpä leviää 
eturauhasta ympäröivän kapselin läpi yleensä hermonympärystilassa. Koepaloissa 
tavattu syöpäkasvu yli kolmen hermon ympärillä osoittautui itsenäiseksi 
ennustetekijäksi hormonihoidetuilla potilailla. Analysoimme myös kolmen 
biologisen merkkiaineen (EZH2, Ki-67 ja MCM7) ennustearvoa 
immunohistokemiallisista värjäyksistä digitaalisella kuva-analyysillä. Näistä solujen 
jakautumisnopeutta kuvaava Ki-67 indeksi yli 10% osoittautui hyödylliseksi 
potilaskohtaista riskiä arvioidessa, erityisesti kohtalaisesti erilaistuneissa 
kasvaimissa (Gleason-summa 7). 
Yhteenvetona todetaan, että väitöskirjan osatöissä löydettiin uusia tapoja vastata 
yhä varhaisemmassa vaiheessa todettujen eturauhassyöpien ja muuttuneiden 
luokitusohjeiden asettamiin diagnostisiin ja ennusteellisiin haasteisiin. 
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ABSTRACT 
A prostate needle biopsy is one of most common types of samples that 
pathologists use to diagnose a malignancy. The main aims of this study were to 
investigate the mechanisms leading to multifocal prostate cancer and to identify new 
diagnostic methods and prognostic markers for prostate needle biopsies. 
Prostatic adenocarcinoma is an architecturally diverse tumor that typically shows 
multifocal growth and several grades. Multiple tumor nodules may arise either from 
microscopic infiltrations of the primary cancer focus or are more likely de novo. 
Apoptosis is also involved in the development of prostate cancer. We studied 
apoptosis regulation in general, with a special emphasis on its role as a possible 
mechanism underlying multifocality. All essential histological features of the 
prostate specimen were sampled using tissue microarrays. The expression of two 
important regulators of apoptosis, BAX and BCL-2, was immunohistochemically 
studied in 1182 foci representing morphologically normal epithelium of cancerous 
prostates, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, 
adenocarcinomas (grades 1 to 5), and capsular perineural invasions. BAX 
expression steadily increased in more malignant phenotypes, while BCL-2 
expression was biphasic, with overexpression observed in prostatic intraepithelial 
neoplasia (PIN) and in poorly differentiated cancers. Interestingly, both proteins 
were overexpressed in a subset of morphologically normal foci of cancerous 
prostates, but not in controls or in cases of hyperplasia. This observation is 
consistent with the field-effect theory, which may explain the multifocality observed 
in prostate cancer. 
Currently, 4000-5000 patients are diagnosed with prostate cancer in Finland 
annually, most of whom are identified by frequent prostate specific antigen (PSA)-
testing of asymptomatic men. Prostate cancer is diagnosed from needle biopsies, and 
an increasing number of biopsies with small foci and atypical features are a 
diagnostic challenge for pathologists. The vast majority of prostate cancers are 
adenocarcinomas, making routine application of immunohistochemistry possible. 
The impact of routine, dual-color immunostaining (2IHC) on diagnostic sensitivity 
and pathologists’ workloads was examined using interval sections from 200 prostate 
needle biopsies. In our 2IHC staining protocol, the neoplastic epithelium was 
visualized with a blue chromogen, and the basal cells were stained brown. Our 
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results suggest that routine 2IHC leads to increased sensitivity and efficiency in 
cancer detection. Most of the small cancers detected with the aid of 2IHC were low-
grade (75%), but a number of very small foci with poorly differentiated cancer 
(25%) were also observed. No minimal criteria for a definitive cancer diagnosis, 
however, have been established. 
In addition to the biological changes observed in more recently diagnosed 
prostate cancers, the Gleason classification system of needle biopsies underwent 
major refinements in 2005. We studied the prognostic value of the modified Gleason 
score (GS) and other histopathological features of needle biopsies from 247 patients 
who were primarily endocrine-treated. Hematoxylin and eosin (H&E)-stained slides 
were scanned, and the evaluation of the digitalized slides was performed using a 
web-based virtual microscope. Our results show that the modified GS is one of the 
strongest independent prognostic factors for primarily hormone-treated patients. 
Moreover, we show that both the worst GS in a single biopsy and the overall GS 
performed equally well as prognostic factors. In addition, the new recommendations 
lead to an increase in GSs in general, and the use of modified the GS may have 
shifted the cut-off between low- and high-grade cancer from GS 6 vs. 7 to GS 3+4 
vs. 4+3. Local spreading of prostate cancer usually occurs through the prostatic 
capsule in the perineural space. More than three foci of perineural cancer invasion in 
the biopsies independently predicted recurrence of the disease in hormone-treated 
patients. In addition, the expression of three promising biomarkers predictive of 
survival (EZH2, Ki-67, and MCM7) was analyzed with the aid of digital image 
analysis. In patients with GS 7, a Ki-67 labeling index greater than 10% 
distinguished patients with an early PSA recurrence.  
In conclusion, new diagnostic applications and prognostic tools for prostatic 
needle biopsies were identified. These methods will hopefully be useful to 
pathologists in the PSA era.
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INTRODUCTION 
 
In the past two decades, prostate cancer has gained special public interest. The 
general awareness of the disease has emerged due to its high incidence and 
prevalence and also because of celebrities with prostate cancer (e.g., Francois 
Mitterrand, Frank Zappa and Robert De Niro).  
The overall incidence of prostate cancer in Finland is approximately 100 cases 
per 100 000. The incidence begins increasing slowly at 45 years of age, and 
maximal incidence is noted between 70 and 74 years. However, even more new 
cases are noted in the age range of 80-84 if data are age-adjusted (1154 per 100 000) 
(Finnish Cancer Registry, Cancer Statistics at www.cancerregistry.fi, updated on 
07.12.2010).  
Between the years 1980 and 2008, the prostate cancer incidence in Finland 
increased four-fold from approximately 1000 annual cases in the early 1980s to 
4215 cases in 2008. In the early 1990s, the number of new prostate cancers 
exceeded that of registered basal cell skin carcinomas, which is usually considered 
the most common malignancy. In the mid-2000s, the incidence of prostate cancers 
exceeded that of breast cancer. Over the past few years, the incidence of prostate 
cancer has slightly decreased, while the number of new breast cancers increased. As 
a result, breast cancer was once again the most common cancer in Finland in 2008 
(Finnish Cancer Registry, Cancer Statistics at www.cancerregistry.fi, updated on 
07.12.2010). A similar decrease in the incidence of prostate cancer was observed ten 
years earlier in the U.S., where testing of prostate specific antigen (PSA) levels was 
first introduced (Quinn and Bapp 2002).  
There are at least three explanations for the observed increased incidence of 
prostate cancer. Two of these include increases in cancer awareness and better 
diagnostic sensitivity in the early 1990s, such as high-resolution trans-rectal 
ultrasound devices and the increased use of needle core biopsies (Cremers et al. 
2010). The most evident explanation for the increased incidence of prostate cancer, 
however, is PSA testing of asymptomatic men (Cremers et al. 2010). 
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Based on clinical follow-up-studies and autopsy specimens, most prostate 
cancers are indolent. In 2008, however, prostate cancer was the second leading 
cause of cancer-related deaths in Finland and in the U.S Furthermore, the annual 
mortality due to prostate cancer increased two-fold between 1980 and 2008 in 
Finland, from approximately 450 to 814 deaths per year. The international trend of 
prostate cancer-specific mortality is slowly rising to approximately 30 deaths per 
100 000 people in Western countries (Quinn and Bapp 2002). Age-adjusted 
mortality for prostate cancer in Finland has decreased in the past few years to 
approximately 15 per 100 000 males (Finnish Cancer Registry, Cancer Statistics at 
www.cancerregistry.fi, updated on 07.12.2010). 
The etiology of prostate cancer remains unknown. The regulation of both normal 
prostate function and prostate cancer is androgen-dependent, and the benefits of 
androgen withdrawal therapy were known seventy years ago (Huggins and Hodges 
1941). There is also a strong genetic predisposition, as evidenced by familiar 
clustering of the disease and twin studies (Steinberg et al.1990, Grönberg et al.1997, 
Lichtenstein et al.2000). Interestingly, most prostatic adenocarcinomas are 
multifocal (Qian et al. 1997), consistent with the cancer field effect theory. There is 
cumulative evidence suggestive of field cancerization of the prostate, including 
gene/protein expression abnormalities and epigenetic changes detected in benign-
appearing epithelium adjacent to cancerous tissue (Chai and Brown 2009, Nonn et al 
2009). 
There are three primary forms of treatment for prostate cancer: active surveillance, 
curative treatments, and endocrine control of cancer (Heidenreich et al.2010, Mottet 
et al. 2011). Surgical treatment of well-differentiated cancer decreases cancer-
specific mortality and morbidity when compared to watchful waiting (Bill-Axelson 
et al. 2005). However, a significant proportion of men diagnosed with low-grade 
cancer can have a favorable long-time prognosis (Albertsen et al. 2005b) and are at 
risk of being overtreated. One treatment option for patients with well-differentiated 
local cancer is active surveillance, which is currently chosen by approximately 10% 
of men (Cooperberg et al. 2007). In contrast to watchful waiting, active surveillance 
refers to intense follow-up and early intervention, if required. In a review by 
Dall’Era et al. (2008), the following conservative criteria were recommended to 
identify suitable candidate patients for active surveillance: PSA value < 10 ng/ml, 
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stable PSA kinetics, Gleason score ≤ 6, cT1-T2a, and a low-volume cancer based on 
at least 12 needle biopsies. In the studies reviewed by Dall’Era et al., commonly 
used criteria for a low-volume cancer were: i) demonstrating fewer than 1/3 positive 
cores and ii) less than 50% involvement in a single core (Dall’Era et al. 2008). 
Preliminary studies of active surveillance indicate that the outcome of these patients 
is not compromised (Klotz 2006). However, because the natural history of prostate 
cancer is often delayed (Johansson et al. 2004), longer follow-up times are required. 
Intent-to-cure treatment options for local cancer are radical prostatectomy, external-
beam radiotherapy or brachytherapy. Patients with locally advanced cancer benefit 
from 3-year adjuvant androgen deprivation therapy (ADT) (Heidenreich et al. 
2010). Metastasized disease is hormonally treated with luteinizing-hormone 
releasing-hormone (LHRH) agonists as a first-line option (Mottet et al. 2011). 
Although almost all patients respond to ADT, the disease eventually progresses if 
the patient lives long enough (Palmberg et al.1999). In such castration-resistant 
disease, the use of docetaxel may prolong life for a few months and is encouraged 
(De Dosso et al. 2008, Mottet et al. 2011). In localized disease, hormone-therapy is 
not associated with better long-term survival (Lu-Yao et al. 2008). The treatment 
chosen for a given patient depends on the patients’ expectations and clinicians’ 
recommendations based on prognostic factors, the most important of which are 
tumor, nodes and metastasis (TNM)-stage, PSA, and Gleason score.  
Chemoprevention of prostate cancer is still under debate. In preliminary trials of 
benign prostatic hyperplasia (BPH), the use of finasteride was associated with a 
reduced incidence of prostate cancer. Since then, several clinical trials have been 
designed to specifically address this issue. Finasteride and dutasteride are inhibitors 
of 5α-reductase (5-ARI), which converts testosterone to the more potent hormone 
dihydrotestosterone. In the Prostate Cancer Prevention Trial, finasteride was shown 
to reduce the risk of prostate cancer by 25% at the end of the seven-year follow-up 
(Thompson et al. 2003). Subsequently, similar results were observed in the 
REDUCE Trial with dutasteride (Andriole et al. 2010). In human cancer cell lines, 
finasteride induces apoptosis in a dose-dependent manner via the BCL-2 and 
BAX/caspase family of proteins (Golbano et al. 2008). Other preventive agents 
currently awaiting validation include cyclo-oxygenase-2 (COX-2) inhibitors, statins, 
and dietary supplements (reviewed by Rittmaster et al. 2009).  
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Frequent testing of prostate cancer has led to earlier detection. The median age at 
the time of detection is now a few years lower than before the PSA screening era 
(Cremers et al. 2010). Cancers detected from elevated PSA levels, are smaller and 
of lower stage and grade than their clinically detected counterparts (Laurila et al. 
2009, Cremers et al. 2010) and may be overlooked by needle biopsies (Wolters et al. 
2010). Many of the small well-differentiated cancers restricted to one biopsy core 
are currently treated by active surveillance, which consists of follow-up PSA tests, 
digital rectal exams (DRE) and repeated biopsies. Due to the aforementioned issues, 
pathologists are increasingly exposed to prostate needle biopsies. The diagnosis of 
very small cancer is subjective, and even the definition of a lower limit of cancer is 
difficult (Van Der Kwast et al.2010). However, small-foci cancers present in 
biopsies often represent clinically significant (GS≥7, bilateral, multifocal or >0.5 cc) 
disease in radical prostatectomy specimens (Boccon-Gibod et al. 2005, Montanari et 
al. 2009). Therefore, the accurate detection of all cancerous foci in prostate needle 
biopsies is important. In addition, it affects prognostic parameters, such as the 
number of positive cores, and thus may directly influence the treatment choice. 
At the same time that cancer detection became earlier, the Gleason scoring system 
went through several refinements (Epstein 2000, Epstein et al. 2005), which 
paradoxically led to increased Gleason scores (Albertsen et al. 2005a, Thompson et 
al. 2005). Thus, a well-differentiated prostate adenocarcinoma today is not the same 
as it was two decades ago (e.g., GS 6 versus 4), which may interfere with the results 
from long-term follow-up studies. In addition, the prognostic impact of the modified 
Gleason scoring system needs to be further evaluated.  
Clearly, there are many challenges for prostate histopathology, and new diagnostic 
aids and prognostic tools are needed.  
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1. Histopathological acinar findings in 
the prostate gland 
1.1 Introductory gross anatomy and physiology 
The prostate gland surrounds the prostatic urethra and the urinary bladder neck 
distal to the bladder. Like the heart and uterus, the prostate is “upside down”, with 
its apex facing downwards and its base facing upwards (Myers et al. 2010). In 1968, 
McNeal proposed a practical concept of dividing the prostate into central, 
transitional, and peripheral zones (McNeal 1968). Anatomical models with lobar 
architecture have also been proposed (Tisell and Salander 1975). However, most 
normal prostates lack lobar architecture (Myers 2000). In more modern prostate 
nomenclature suggested by urologists and anatomical pathologists at the Mayo 
Clinic, the use of the term “central zone” is considered problematic because it can 
become confused with the central part of gland (Myers et al. 2010). The use of the 
term “lobe” is also discouraged (Myers et al.2010). 
Seminal vesicles and the ductus deferens fuse to form two ejaculatory ducts, which 
enter the prostate at the base. These ducts continue in the midline, anterior to the 
peripheral zone, to the verumontanum, where they open to the urethra (Myers et al. 
2010). The apex, basis and zones are important to distinguish because of the 
different cancer frequencies, cancer grades, and surgical implications associated 
with these regions (Cohen et al. 2008). 
Functionally, the prostate gland is an additional reproductive organ that 
contributes to the viscosity of the semen by secreting enzymes, including PSA, 
prostatic acid phosphatase (PAP), and alkalic phosphatase (AP). PSA is a 
chymotrypsin-like glycoprotein that slowly hydrolyzes peptide bonds, thereby 
liquefying semen. Some of the enzymes secreted by the prostate can be detected in 
circulating blood (e.g., PAP, AP and PSA) and used for diagnostic purposes 
(Stamey et al.1987, Barichello et al.1995, Strohmaier et al. 1999). 
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1.2 Normal prostate histology 
The peripheral part of the prostate gland consists of small glands (“acini”) that drain 
to ducts, which fuse to form bigger ducts. These eventually drain into small 
openings of the prostatic urethra. Benign prostatic acini are lined with a double-
layered epithelium (McNeal JE 1988). The luminal compartment of the epithelium 
consists of cuboidal to columnar cells with abundant, clear cytoplasm, the amount of 
which depends on the secretory activity of the gland (Figure 1). The outermost layer 
consists of flat, triangular cells with small nuclei and scarce cytoplasm, the so-called 
basal cells. There is zonal variation of the normal morphology. For example, the 
morphology of central zone glands is between that of the peripheral glands and 
seminal vesicles. 
 
 
Figure 1. Benign histology of the prostate. Luminal (L) epithelial cells are columnar and 
have clear, abundant cytoplasm. The glands are lined by basal cells (arrowheads). 
Occasionally, psammoma-like bodies referred to as corpora amylacea may be observed 
inside the glands (arrow). H&E staining (200 x). 
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1.3 Benign prostatic hyperplasia 
Benign prostatic hyperplasia (BPH) is a common cause of prostate enlargement 
that leads to clinically significant bladder outflow obstruction in approximately 
40% of men (Djavan 2010, Roehrborn 2011). Most often, the histological 
changes associated with BPH are noted in the periurethral region (Myers 2000). 
The first change consists of an increased amount of smooth muscle and less 
elastic tissue than the normal stroma. These events are followed by hyperplasia of 
the periurethral glands (Rosai 1996). The glands are often dilated and have a 
cytologically benign-appearing epithelium with inconspicuous nucleoli (Rosai 
1996).  
The diagnosis of BPH is often clinical and based on symptomatic prostatism, 
DRE, serum PSA value, free/total PSA %, and findings on 
transrectal/transabdominal ultrasound. Treatment of symptomatic BPH is now 
primarily through pharmaceuticals including 5-ARI and/or alfa-blockers 
(reviewed by Tacklind et al. 2010). In cases of severe obstruction, hyperplastic 
nodules are resected transurethrally (TURP), and the diagnosis can be confirmed 
histologically. However, no correlations have been identified between 
histopathological parameters from needle biopsies and prostatic volume, or 
urinary obstructive symptoms (Viglione et al. 2002). Therefore, BPH cannot 
reliably be diagnosed using prostatic needle biopsies (Viglione et al. 2002). 
1.4 Benign mimickers of prostate cancer 
The most common benign mimickers of cancer are atrophy and foci of crowded 
glands with atypical features or atypical adenomatous hyperplasia (AAH, or 
adenosis) (Bostwick and Chang 1999). Other commonly known diagnostic pitfalls 
include; verumontanum hyperplasia, clear cell cribriform hyperplasia, nephrogenic 
adenoma and hyperplasia of the mesonephric ducts (Young 1988, Molinie et al. 
2004). Basal cell hyperplasia (BCH) and atypical BCH can resemble both high 
grade prostatic intraepithelial neoplasia (HGPIN) and adenocarcinoma (Epstein and 
Armas 1992). Most of the lesions are readily distinguished from adenocarcinoma by 
the presence of basal cells and/or negative immunostaining for alpha-methylacyl-
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CoA racemase (AMACR). Atypical BCH shows a multilayer staining pattern for the 
basal cell markers p63 and CK34betaE12 (Figure 2.) (Rioux-Leclercq and Epstein 
2002). Because in cases of partial atrophy even the immunostaining pattern can 
resemble carcinoma, the differential diagnosis is based primarily on the glandular 
architecture of the H&E-staining (Herawi et al. 2005). 
 
 
Figure 2. A focus containing atypical BCH. Left: nuclear atypia, hyperchromasia and 
stratification, H&E staining (100 x). Right: dual-color immunostaining shows intense brown 
staining of the basal cell layer with p63 and CK34betaE12 while luminal epithelial cells stain 
negative for AMACR (100 x).  
1.5 Premalignant and suspicious lesions 
1.5.1 High-grade prostatic intraepithelial neoplasia (HGPIN) 
Historically, prostatic intraepithelial neoplasia was divided into three grades 
based on their morphological features (Sakr et al. 2004). Due to the problems 
associated with low reproducibility, this approach has been abandoned. Currently, 
the WHO recognizes two entities, low-grade and high-grade prostatic intraepithelial 
neoplasia (LGPIN and HGPIN), but only the latter has been shown to be associated 
with cancer (Qian et al 1997, Bostwick et al.1999, Sakr et al 2004). High-grade 
prostatic intraepithelial neoplasia is defined by the WHO as a neoplastic 
transformation of the epithelium lining the prostatic ducts and acini (Sakr et al 
2004). Cytopathological features of HGPIN include a nearly uniformly increased 
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nuclear/cytoplasm-ratio, prominent nucleoli, and coarse chromatin. Typically, 
HGPIN presents multiple architectural patterns in combinations: tufted (97%), 
micropapillary (66%), flat (21%) or cribriform (19%) (Qian et al 1997). In addition, 
there are four variants recognized by the WHO: foamy, mucinous, signet-ring cell, 
and inverted HGPIN (Sakr et al 2004). In LGPIN, the diagnostic features are similar 
to HGPIN, but more inconspicuous and unevenly distributed (Sakr et al 2004). 
HGPIN has morphological analogues in various organs, such as high grade 
dysplasia or carcinoma in situ of the colon or breast. It also shares molecular and 
genetic changes with adenocarcinoma (Qian et al. 1995, Meeker et al. 2002).  
Recent studies of prostate needle biopsies have not shown an elevated risk of 
cancer in repeated biopsies for HGPIN, although the spatial association of HGPIN 
and adenocarcinoma in prostatectomy specimens is well-known (Postma et al. 2004, 
Laurila et al. 2009). It is believed that the significance of HGPIN in predicting 
cancer has diminished because of the sextant biopsy protocol, through which the 
majority of the cancers are detected (Herawi 2006). A recent Canadian study 
indicates, however, a strong association between HGPIN and subsequent 
adenocarcinoma on repeated biopsies. This study also reported a linear relationship 
between the extent/multifocality of HGPIN and cancer risk (Srigley et al. 2010). 
Recent molecular evidence also demonstrates that TMPRSS2:ERG gene fusion-
positive HGPIN is associated with the same fusion status in matched cancer, a 
finding that could be used as a criterion for clinically significant HGPIN (Mosquera 
et al. 2008). However, the prognostic significance of TMPRSS2:ERG gene fusion in 
adenocarcinoma is yet to be determined (Attard et al. 2006, Saramäki et al. 2008). 
Overdiagnosis of HGPIN is not uncommon (Bostwick and Ma 2007). Benign 
lesions in the differential diagnosis of HGPIN are atypical BCH (Figure 2) and 
benign central zone glands (Epstein and Armas 1992, Rioux-Leclercq and Epstein 
2002, Bostwick and Ma 2007). The most important malignant lesions in the 
differential diagnosis of HGPIN are intraductal carcinoma and ductal carcinoma, 
which may be difficult to distinguish based on morphological criteria alone (Pickup 
and Van Der Kwast 2007). An example of HGPIN is shown in chapter 1.6 (Figure 
4). 
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1.5.2 Proliferative inflammatory atrophy (PIA) 
Proliferative inflammatory atrophy (PIA) has been linked to prostate carcinogenesis 
via HGPIN or via direct progression to cancer (De Marzo et al. 1999, De Marzo et 
al. 2003, Wang 2009). Epigenetic alterations, such as hypermethylation of cytidine-
guanidine (CpG)-islands of the glutathione S-transferase P1 (GSTP1) gene 
promoter, have been noted in PIA lesions. These alterations may lead to cumulative 
genetic damage due to oxidative stress (De Marzo et al. 2003). The current 
understanding of PIA suggests that it is a benign lesion with a certain degree of 
genetic instability and that it can degenerate into prostate intraepithelial neoplasia or 
carcinoma (Woenckhaus and Fenic 2008). However, the clinical impact of PIA has 
not been confirmed, and it is not a routinely diagnosed entity in pathology reports. 
An example shown in Figure 3. 
 
 
Figure 3. A focus of proliferative inflammatory atrophy (PIA) showing a few intraluminal 
neutrophils and regenerative epithelium of atrophic glands, H&E staining (200 x).  
1.5.3 Atypical small acinar proliferation (ASAP) 
Atypical small acinar proliferation (ASAP) does not exist as a discrete 
morphological entity but is a valid diagnosis (Iczkowski et al. 1999). The diagnosis 
of ASAP/suspicious for cancer is used when there are crowded glands with 
malignant features, but the focus is either too small to be considered cancer or does 
not fulfill the three major criteria of cancer (see 1.6 Adenocarcinoma). Most ASAP 
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diagnoses can be resolved to either benign or cancer with the aid of 
immunohistochemistry (Ng et al. 2007). Uniform requirements for diagnosing 
adenocarcinoma are lacking (e.g., the minimum number of glands). Before AMACR 
was introduced in the beginning of the 21st century, there were no positive markers 
for cancer, and the diagnosis of adenocarcinoma was based primarily on H&E 
staining. During that era, the median number of glands in foci diagnosed with ASAP 
was 11 and in cancerous foci was 17 (Bostwick and Iczkowski 1997). Currently, the 
number of glands needed for a cancer diagnosis by a uropathologist varies among 
between 2 and 10 (Egevad et al. 2006, Humphrey 2007). Other authorities 
recommend that no universal lower limit of glands can be assessed and that 
pathologists may diagnose cancer whenever they feel comfortable with the 
diagnosis (Van Der Kwast and Epstein 2010). 
1.6 Adenocarcinoma 
Approximately 80% of prostate cancers arise in the peripheral zone, 15% in the 
periurethrally located transitional zone, and 5% in the central zone of prostate 
(Cheng et al. 2005, Cohen et al. 2008). The observed frequencies roughly correlate 
with the different zone volumes (ml).  
There are three uniformly accepted major criteria for prostate cancer diagnosis:  
• Architectural disturbance: infiltrative small glands or cribriform glands too 
large or irregular to represent HGPIN 
• Single cell layer (absence of basal cells) 
• Nuclear atypia: nuclear and nucleolar enlargement (Iczkowsky et al. 1999, 
Humphrey 2007)  
The same major criteria were recognized by Totten and his colleagues in the 1950`s 
(Totten et al. 1953).  
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Additional minor criteria may be used as helpful hints toward an adenocarcinoma 
diagnosis. These include (Algaba et al. 1996): 
• Intraluminal wispy blue mucin (blue-tinged mucinous secretions) 
• Pink amorphous secretions 
• Mitotic figures 
• Intraluminal crystalloids (see Figure 4) 
• Adjacent HGPIN 
• Amphophilic cytoplasm 
• Nuclear hyperchromasia  
 
In a survey of genitourinary pathologists by Egevad et al. (2006), four features were 
considered pathognomonic for prostate cancer. These were reported as follows by 
the participants: glomeruloid bodies (58%) (Figure 5), collagenous micronodules 
(also termed mucinous fibroplasias) (64%), circumferential perineural invasion 
(84%), and growth in fat (36%).  
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Figure 4. Small glands represent well-differentiated adenocarcinoma with a Gleason score 
3+3=6. Eosinophilic amorphous secretions and cristalloids (arrow) can be noted inside the 
lumina of the glands. An adjacent HGPIN (H) shows an increased nucleus/cytoplasm ratio, 
hyperchromatic nuclei, amphophilic cytoplasm, and (cribriform) stratification of the 
epithelium. Basal cells are evident. H&E staining (200 x). 
 
 
 
Figure 5. Glomeruloid structures are considered pathognomonic for prostate cancer. Left: 
H&E staining. Right: dual-color immunostaining (2IHC) showing strong positivity for AMACR 
and negative staining for basal cells (100 x). 
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2. Prostate cancer diagnostics in the 
PSA era  
2.1 The impact of prostate specific antigen 
Before PSA testing was introduced in late 1980s by Stamey and colleagues (1987), 
cancers were diagnosed by clinical symptoms, and needle biopsies were generally 
directed against a palpable mass (Mikuz 1997). Although PSA testing is now widely 
used in daily health care, the rationality of population-based PSA screening is still 
under debate (Barry 2009). Beginning five years after the inception of the PSA test, 
mortality due to prostate cancer has declined 4% annually in the U.S. (Ries et al. 
2008). In the European Randomized Study of Screening for Prostate Cancer, PSA 
screening of 50-74-year-old men was associated with a significant decline in 
mortality. This achievement, however, was at the cost of a remarkable risk of 
overtreatment (Schröder et al.2009). At the same time, Andriole (2009) found no 
differences in prostate cancer-related mortality between PSA-screened and control 
patients during a 7-10-year follow-up (Andriole et al. 2009). In the U.S., most men 
over 50 years of age have been tested for serum PSA values (Ross et al. 2008). 
Moreover, 95% of urologists of the same age have had their PSA tested (Chan et al. 
2006).  
Cancers detected by screening are smaller and better differentiated than 
symptomatic cancers (Laurila et al. 2009). The more PSA tests are taken, the earlier 
cancers are detected, and the less cancerous tissue is observed in needle biopsies. 
Small, atypical foci are common, and a definitive cancer diagnosis is often difficult, 
resulting in considerable interobserver variability in the diagnosis of small, atypical 
lesions (Van der Kwast et al. 2010). Therefore, auxiliary immunohistochemical 
diagnostic tools have been developed. 
29 
2.2 Immunohistochemistry 
 
2.2.1 Basal cell markers 
Adenocarcinoma can be differentiated from benign glands by the absence of basal 
cells. However, it is not always a simple matter to distinguish basal cells in H&E-
staining. The first markers aiding in the differential diagnosis of prostate cancer 
were basal cell layer markers, including MA-903, CK-903, and CK-
HMW/CK34betaE12 (O´Malley et al.1990, Shah et al.1991). Various basal cell 
markers have been in use since immunohistochemical stainings were introduced into 
the clinical routine. The most commonly analyzed basal cytokeratins are 
CK34betaE12 and CK5/6 (Berney et al. 2005). Alternatively, the nuclear marker 
p63 may be used. Both CK34betaE12 and p63 are highly specific for basal cells 
(effectively 100%), with p63 demonstrating a slightly better sensitivity (Shah et al. 
2002, Garcia et al. 2007). Because the basal cell layer is interrupted in the lesions 
most critical to differential diagnosis (HGPIN and AAH), basal cells are best 
visualized by co-staining for p63 and CK34betaE12 (Zhou et al. 2003, Jiang et al. 
2005, Boran et al. 2010). In addition, co-staining is useful due to zonal variations in 
the immunophenotype of basal cells in the peripheral and transitional zones (Garcia 
et al. 2007).   
2.2.2 Alpha-methylacyl-CoA racemase (AMACR, P504S, 
racemase) 
Alpha-methyl-CoA racemace (AMACR) is a positive marker for prostatic 
neoplasias and was discovered using a high-throughput genetic analysis (Xu et al. 
2000, Jiang et al. 2001). Since its identification, numerous studies have confirmed 
that it is specifically expressed in several dysplasias of other organs, such as 
Barret’s esophagus and dysplasias associated with inflammatory bowel disease 
(Dorer and Odze 2006). In addition, AMACR is expressed in various malignancies, 
including adenocarcinoma of the esophagus and gastric and colon cancers (Dorer 
and Odze 2006, Lin et al. 2007, Truong et al. 2008). AMACR has high specificity 
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and sensitivity in the detection of HGPIN and prostatic adenocarcinoma (Jiang et al. 
2001, Browne et al. 2004, Magi-Galluzzi et al. 2003), although there are variations 
between laboratories (Magi-Galluzzi et al. 2003). Since the introduction of AMACR 
approximately ten years ago, there have been several studies showing its usefulness 
in identifying prostate cancer and HGPIN (Browne et al. 2004, Carswell et al. 
2006). AMACR expression is modulated by hormonal therapy, which is an 
important diagnostic pitfall to keep in mind when assessing follow-up biopsies after 
treatment (Sung et al. 2007).  
 
2.2.3 Dual-color immunostains 
The basic technique of dual-color horseradish peroxidase and alkaline-
phosphatase immunostaining has been available for at least three decades (Valnes 
and Brandtzaeg 1984). Advances in the staining protocol and widespread use of 
immunostaining have now permitted their routine use. The antibodies in a given 
cocktail can be visualized with different commercially available chromogens, 
resulting in double-chromogen, or dual-color, stains (e.g., HistoBlue, Multivision 
kit; Vector Blue, Vector Laboratories, Inc., Burlingame, CA, USA; LPRed, Dako 
Denmark A/S, Glostrup, Denmark; Vector Red, Vector Laboratories, Inc., 
Burlingame, CA, USA). The specific combination of dual-color staining depends on 
the laboratory equipment. In dual-color stains, the diaminobenzidine (DAB)-
horseradish peroxidase reaction is commonly used to stain the basal cell 
compartment brown. Alkaline-phosphatase activity assays using blue or red 
chromogens (e.g., Vector Blue and Vector Red, Vector Laboratories, Inc., 
Burlingame, CA, USA) are used to stain neoplastic epithelium. A cocktail of two 
antibodies for basal cells (e.g., p63 and CK-HMW, both DAB-brown) and one for 
neoplastic epithelium (AMACR, blue) enables three-antibody, two-chromogen 
staining. 
Dual-color immunostainings are especially useful in the evaluation of prostate 
biopsies containing small foci suspicious for carcinoma or ASAP (Molinie et 
al.2004, Jiang et al.2005, Trpkov et al.2009). The major advantages are that both 
basal cells and neoplastic epithelium are visualized simultaneously on the same slide 
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with different colors (Figure 12 C and D), and the limited biopsy tissue available in 
the paraffin blocks is not exhausted as rapidly as with two separate immunostained 
slides (Hameed and Humphrey 2009).    
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3. Grading of prostate cancer 
3.1 Gleason score - historical aspect 
 At least forty grading systems have been suggested for prostate adenocarcinoma 
(Humphrey PA 2003). One of the oldest and most used is the Gleason grading 
system, first published in the late 1960s (Gleason 1966, Mellinger et al. 1967). The 
World Health Organization (WHO)-Mostofi grading system has been widely used 
together with the Gleason system. In the original Mostofi grading system, both the 
architectural pattern (glandular differentiation) and nuclear grade (anaplasia) are 
combined to form three grades (Mostofi 1975). Later, a suggested modification by 
Dr. Mostofi´s group incorporated the count of mitotic figures to form five 
prognostic classes (Schroeder 1985). Although a high nuclear grade (gr. III) is 
associated with a high Gleason grade, the nuclear grade is sensitive to tissue fixation 
artifacts (Zhou et al. 2001). Therefore, determination of the nuclear grade is now 
avoided in many centers. 
Several modifications to the original Gleason system have been suggested by Dr. 
Gleason (1974) himself, McNeal et al. (1986), and others. Despite gradual, minor 
adaptations, the Gleason score (GS) has stood the test of time as one of the most 
powerful prognostic factors for prostate cancer. As a system, the GS is an exception 
amongst grading systems of human cancers. While other grading systems are based 
on three or four grades, in the GS system the predominant and second most common 
cancer patterns are graded from 1 to 5 and summed to form a GS between 2 and 10 
(Gleason 1966). The original patterns depicted by Dr. Gleason are shown in Figure 
6. 
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Figure 6. The classical Gleason patterns showing gradually increasing levels of 
dedifferentiation from 1 to 5. Reprinted by permission of Macmillan Publishers 
Ltd:[Modern Pathology](Humphrey 2004), copyright (2004). 
3.2 Contemporary Gleason score - what is new? 
In 2005, the International Society of Urological Pathology (ISUP) organized a 
consensus conference that yielded the first major revision of the original Gleason 
scoring system. Previously, GSs were reported to suffer from low reproducibility 
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and high interobserver variability among pathologists, although uropathologists 
performed slightly better (Alsbrook et al. 2001a, Alsbrook et al. 2001b). There was 
also need to update the system because of Gleason grade inflation and because 
upgrading of the GS following a radical prostatectomy was common. Several 
modifications were suggested and adapted worldwide, resulting in a “modified GS”. 
These modifications have resulted in improved reproducibility, better correlations 
between the GS of the biopsy and the radical specimen, and a likely shift in the 
prognostic cut-off between low-grade and high-grade cancers from GS 6 vs. 7 to GS 
3+4 vs. 4+3 (Helpap and Egevad 2006, Billis et al. 2008, Fine and Epstein 2008, 
Helpap and Egevad 2008, Fanning et al. 2009, Helpap and Egevad 2009).  
In the original drawing of Gleason grades (Figure 6), there is a significant overlap 
between various grades. Cribriform structures are noted in all grades except Gleason 
grade 1, and gland fusion is noted on both sides of the dashed line between grades 3 
and 4. Humphrey (2004) suggested that the original Gleason grade 1 may represent 
AAH and that before a diagnosis of GS 1+1=2 cancer is given the presence of any 
basal cells must be excluded. The 2005 ISUP uropathologist consensus statement 
stated that a GS 1+1=2 should not be used for any specimen type (Epstein et al. 
2005). Additionally, it is likely that the original cribriform Gleason grade 3 patterns 
of carcinoma would currently receive a diagnosis of cribriform HGPIN if 
immunostains were performed (Amin 1994). A true fusion of the glands is always 
regarded as grade 4 according to the modified Gleason score (Epstein et al. 2005). 
In the ISUP Consensus Conference, cribriform structures are accepted as Gleason 
grade 3 provided that they have a round contour and are size of normal glands 
(Epstein et al. 2005). However, in a subsequent study representing only cribriform 
cancerous glands of putative Gleason grade 3 cases as defined above, most expert 
uropathologists graded all cribriform glands as Gleason grade 4 (Latour et al. 2008). 
Currently, it is recommended that all cribriform glands are graded Gleason grade 4 
(Epstein JI 2010). Another evident change when comparing the old drawing (Figure 
6) with the contemporary version (Figure 7) is that small, separate glands without 
lumina are considered as poorly differentiated and given a Gleason grade 4 (Figure 
7). Infiltrating single cancer cells and strands of cancer cells, analogous to “indian 
files” in lobular carcinoma of the breast, are clearly depicted as Gleason grade 5. A 
solid pattern with or without comedonecrosis is another pattern accepted as Gleason 
grade 5. 
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Figure 7. Refined Gleason patterns according to the modified Gleason 
scoring system. In general, the picture is more consistent with current 
recommendations than the original picture by Dr. Gleason (Figure. 6). 
However, some details are already discrepant with current 
recommendations. For instance, all cribriform structures should be under 
grade 4, with the exception of comedonecrosis. There is also some 
overlap of the smallest glands with minimal lumens from grade 3 up to 
grade 5. Reprinted with permission of Wolters Kluwer Health (from 
Epstein et al. 2005). 
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3.3 Grading of morphological variants of prostatic 
adenocarcinoma 
3.3.1 Atrophic pattern adenocarcinoma 
The atrophic variant of prostatic adenocarcinoma morphologically resembles 
atrophic benign glands with open lumens and a single-layered, flattened epithelium. 
However, cytologic atypia with enlarged nuclei and macronucleoli are noted at 
higher magnifications (Srigley 2004). This variant can be graded based on 
architecture using the Gleason pattern technique (Humphrey 2004). 
3.3.2 Pseudohyperplastic adenocarcinoma 
This variant is characterized by dilated glandular structures with a single layer of 
epithelial cells. Cells may show abundant cytoplasm similar to hyperplastic cells. 
Lack of the basal cells is easily demonstrated by immunohistochemistry (IHC) 
(Figure 8). The pseudohyperplastic variant is graded as Gleason grade 3 by most 
uropathologists of the ISUP consensus panel (Epstein et al. 2005). 
 
 
Figure 8. Left: benign-appearing dilated glands with a single-layered luminal epithelium, 
H&E staining. Right: dual-color staining reveals a lack of basal cells and uniform positivity 
for AMACR. Squamous epithelium noted on the top of the right-hand picture serves as an 
internal control for the basal cytokeratin stain (100 x). 
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3.3.3 Foamy gland carcinoma 
Foamy gland carcinoma was characterized by Nelson and Epstein (1996) as 
consisting of glands with cytologically benign-appearing cells with abundant 
xanthomatous cytoplasm (Figure 9). In most cases, cells lack prominent nucleoli, 
which is one of the three major criteria used to diagnose prostate cancer (Nelson and 
Epstein 1996). The foamy appearance of the tumor cells results from numerous 
alcian blue-positive intracytoplasmic vesicles (Tran et al. 2001). Glandular 
formation is usually consistent with Gleason pattern 3 (Epstein et al. 2005). 
However, some of these tumors may behave aggressively (Tran et al. 2001). 
 
 
Figure 9. Foamy gland carcinoma. Cancer cells have xanthomatous-appearing cytoplasm 
and very small, benign-appearing round nuclei. H&E staining (200 x). 
 
3.3.4 Colloid (mucinous) adenocarcinoma 
Earlier, mucinous variants by definition were considered as Gleason grade 4 
(Humphrey 2004). Most mucinous cancers are have a Gleason grade 4 pattern 
resembling cribriform irregular glands floating within a mucinous matrix, but the 
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glandular formation may occasionally be closer to that of Gleason grade 3 (Figure 
10.) (Epstein et al. 2005). The current consensus of uropathologists is that mucinous 
carcinomas should be graded based on glandular formation, which is usually of 
grade 4 but sometimes of grade 3 (Epstein et al. 2005). The prognostic significance 
of this refinement is unknown.  
 
 
Figure 10. Mucinous adenocarcinoma showing extracellular mucin production. Mucin is 
predominantly intraglandular but also leaks to the stroma. Glandular formation is most 
easily observed on the right image (2IHC), where most of the glands are fused (Gleason 
pattern 4), but separate glands are also evident (Gleason pattern 3) (100 x). 
3.3.5 Signet-ring cell carcinoma 
This variant appears similar to signet-ring cell cancers in other locations. Glandular 
formation is absent, and the cells produce intracellular mucin, protruding flattened 
nuclei to the periphery. When these cells are present in significant amounts (>25%), 
the cancer is referred to signet-ring cell cancer. This variant represents the most 
aggressive Gleason grade of 5. According to the original studies by Dr. Gleason, the 
signet-ring cell variant is very rare (Humphrey 2004). Intracytoplasmic vacuoles, 
however, are common in prostatic adenocarcinoma and should be considered 
separately from mucin-containing signet-ring cells (Figure 11) (Epstein et al. 2005). 
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Figure 11. Poorly differentiated adenocarcinoma of a GS 5+5=10 cancer showing 
intracytoplasmic vacuoles resembling signet-ring cells (arrowheads). However, this is not 
considered a true signet-ring cell cancer. Perineural invasion is thought to be one of the few 
pathognomonic features for prostate cancer (arrow). H&E staining (200 x).  
3.3.6 Other variants of acinar adenocarcinoma 
In the clear cell/hypernephromatoid variant, cells have abundant cytoplasm and 
small nuclei. Tightly packed or fused glandular structures with a small lumen may 
form. Although this pattern resembles well-differentiated clear cell renal cell 
carcinoma of Fuhrman grade 1, it behaves aggressively and actually forms the 
original Gleason grade 4 cancer (Gleason et al.1966). 
Other rare variants recognized by the WHO include the oncocytic, 
lymphoepithelioma-like, and sarcomatoid variants (carcinosarcoma) (Epstein et al. 
2004). 
3.3.7 Ductal adenocarcinoma and comedocarcinoma 
 
Ductal adenocarcinoma is defined by the WHO as a “subtype of adenocarcinoma 
composed of large glands lined by tall pseudostratified columnar cells” (Yang et al 
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2004). Intraductal papillary fronds or cribriform structures are considered 
characteristic (Brinker et al. 1999). The three subtypes of ductal adenocarcinoma 
recognized by the WHO are the papillary, cribriform, and solid types (Yang et al. 
2004). Glandular elements resembling endometrial carcinoma may also be noted, 
although use of term “endometrioid carcinoma” is discouraged by the WHO (Yang 
et al 2004). In ductal carcinoma, the cytoplasm is usually amphophilic, and basal 
cells are rarely noted (Yang et al 2004). The major differential diagnoses are with 
intraductal carcinoma and cribriform HGPIN. Ductal carcinomas are mostly 
equivalent to Gleason grade 4 as recommended by the ISUP 2005 consensus panel 
(Epstein et al. 2005) and the WHO (Yang et al. 2004). Ductal carcinoma with 
central comedonecrosis is graded as Gleason grade 5 (Humphrey 2004, Yang et al. 
2004). 
Ductal carcinoma is still a debated concept. Although diagnostic criteria have 
been established, there is no molecular or even morphological evidence that ductal 
carcinoma is a separate entity (Pickup and Van Der Kwast 2007). The largest 
published series, consisting of 371 cases of ductal adenocarcinoma, showed an 
association with increased disease-specific mortality risk and significantly lower 
PSA values when compared to normal acinar-type adenocarcinoma (Morgan et al. 
2010). These 371 ductal carcinomas were identified from a register containing 
443 251 prostate cancer patients, with a reported incidence of only 1:1195 cancers 
(Morgan et al. 2010). In another study by Bock and Bostwick (1999), 5% of 
peripheral acinar cancers showed features traditionally associated with ductal 
cancer, namely papillary and cribriform growth patterns and a lack of basal cells. 
Thus, ductal features are more common in regular peripheral adenocarcinoma than 
in presumed central cancers of ductal origin. Moreover, the nomenclature is 
ambiguous and warrants classification under conventional types of adenocarcinomas 
(Pickup and Van Der Kwast 2007). In conclusion, the current expert opinion is that 
if “pure” ductal carcinoma of the prostate exists, it is rare. 
 
41 
3.4 Reporting prostate needle biopsies 
In 2005, the Gleason grading system of needle biopsies experienced its first major 
revision (Epstein et al. 2005). The so-called modified Gleason grading system is 
based on the opinions of the consensus panel of the world’s leading uropathologists 
at the 2005 ISUP Consensus Conference. The most important new recommendations 
of the conference were: 
• The most aggressive Gleason pattern should always be incorporated as a part 
of the GS, regardless of its area (even if <5%) 
• A Gleason score of 1+1=2 should not be used (in any type of specimen) 
• A small area (<5%) of less aggressive cancer should be ignored 
Prior to the ISUP Consensus Conference, Epstein (2000) suggested that a diagnosis 
of GS 2-4 adenocarcinoma could be assessed “rarely if ever” based on needle 
biopsies. This statement was based on several observations. First, a large amount of 
radical prostatectomy samples at Johns Hopkins showed that all cancers diagnosed 
with GS 2-4 on needle biopsies were upgraded on subsequent radical 
prostatectomies. Second, because GS 2-4 cancers arise in the transitional zone, they 
are not usually biopsied. Third, GS 2-4 cancers are round nodules by definition; it is 
impossible to see the edges of an entire nodule in a biopsy core. 
All of the aforementioned recommendations have now been generally accepted and 
show an improved correlation with radical specimens (Helpap and Egevad 2006, 
Billis et al. 2008). However, it has been shown that older pathologists still diagnose 
GS 2-4 adenocarcinomas on needle biopsies more frequently than their younger 
colleagues (Egevad et al. 2005). 
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3.5 Current controversies 
One of the most concerning issues regarding prostate needle biopsies today is the 
lack of standardized manufacturing. The practice varies between the USA and 
Europe and between countries and laboratories. In a recent, unpublished survey by 
the European Network of Uropathologists (ENUP), slightly more than half of 
laboratories process prostate needle biopsies individually, while the rest use some 
form of pooled biopsy protocols (between 2 and 6 biopsies per block) (Lars Egevad 
2011, personal communication). Because the processing method used affects 
reporting of prostate needle biopsies, there are direct clinical and prognostic 
implications. Clinicians and uropathologists should be aware that the Gleason 
system used impacts patient prognosis and treatment (Montironi et al. 2010). The 
ISUP recommends assessing the worst GS based on needle biopsies submitted in 
separate containers (Epstein et al. 2005). However, the ISUP panel did not reach a 
consensus for cases in which multiple cancer-containing cores are submitted in one 
specimen container (Epstein et al. 2005). Moreover, when multiple cores are 
positive, Europeans more frequently report an additional overall GS at the end of the 
pathology report (Egevad et al. 2005). In addition, although cancers are now 
identified at earlier stages, Gleason scores have been increasing for the last two 
decades in the absence of a true biological change (Albertsen et al. 2005a). 
Changing scoring systems together with variable processing and reporting methods 
are suboptimal contexts in which to ask clinicians to make the best treatment 
choices.  
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4. Prognostic factors in prostate 
cancer 
4.1 Prostate-specific antigen (PSA)  
The pre-treatment serum PSA value (ng/ml) is not only a diagnostic marker for 
prostate cancer but also one of the strongest prognostic factors for this disease 
(Partin 2001, Graff et al. 2007). The PSA value may be used in patient follow-up as 
a surrogate marker for disease progression (Stamey et al.1987, Strohmaier et al. 
1999). If post-treatment PSA values remain low for a 5-year period, the probability 
of subsequently developing metastasis is approximately 1% (Stock et al. 2009). In 
addition, response in PSA value is an independent prognostic factor for patients 
treated with endocrine therapy (Palmberg et al. 1999). In rare instances, the PSA 
value cannot be reliably used as a prognostic marker for some variants of prostate 
cancer, such as small cell cancer and possibly “true” ductal carcinoma (Brinker 
1999, Wang and Epstein 2008, Morgan et al. 2010).  
4.2 Gleason score 
Forty years since its inception, the Gleason score has remained the most widely 
used grading system because of its extremely strong prognostic value (Partin et al. 
2001, Egevad et al. 2002, Stephenson et al. 2005, Graff et al. 2007, Waltz et al. 
2009). The scores, however, have changed over time due to stage migration and 
grade inflation, the so-called Will Rogers phenomenon, which is well known in 
various cancers, including prostate cancer (Thompson et al. 2005). The predominant 
and the second most common Gleason patterns are no longer combined per se, due 
to the following adaptations to the original GS system: 
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• In the case of a radical prostatectomy specimen with separate tumor 
nodules, the grade of the dominant tumor nodules is recommended 
(Epstein et al. 2005) 
• Because it is unlikely that, for instance, a GS 2+2=4 central nodule 
would change the poor prognosis associated with a peripheral, 
undifferentiated cancer, the GS needs to be assessed only from the 
aggressive nodule (Epstein et al. 2005). 
There is also some evidence suggesting that the most aggressive Gleason grade 
today may be a stronger prognosticator than the original Gleason score (Vis et al. 
2007). 
 
4.3 Clinical tumor, nodes and metastasis (cTNM) – 
stage 
The clinical tumor stage (cT-stage) has previously been an important 
prognosticator. However, frequent PSA testing has led to the detection of smaller 
cancers, which are unpalpable in a DRE. In addition, nearly one third of cT-stages 
are incorrectly assessed for other reasons (Reese et al. 2011). In conclusion, the cT-
stage may lack independent prognostic power in the PSA era, most likely due to 
changes in the detectable volume of cancer by urologists and radiologists and 
because of better predictive parameters in core biopsies (Reese et al. 2011). 
4.4 Prognostic findings from the radical prostatectomy 
specimen 
4.4.1 Pathological tumor, nodes and metastasis (pTNM) -stage  
Pathological tumor stage (pT-stage) is based on the evaluation of a radical 
prostatectomy specimen. The specimen should be completely embedded in a 
paraffin block, preferably on a macroblock, which are especially useful for assessing 
tumor volume, multifocality and marginal positivity. According to the TNM 
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Classification of Malignant Tumours – 7th Edition by the International Union 
Against Cancer (UICC), the following rules are applied in pathological staging of 
prostate cancer: 
 
pTX. Primary tumor cannot be assessed 
pT0. No evidence of primary tumor 
pT2. Tumor confined within prostate 
pT2a. Tumor involves one half of one lobe or less 
pT2b. Tumor involves more than half of one lobe, but not both lobes 
pT2c. Tumor involves both lobes 
pT3. Tumor extends through the prostatic capsule1 
pT3a. Extracapsular extension (unilateral or bilateral), including microscopic 
bladder neck involvement 
pT3b. Tumor invades seminal vesicle(s) 
pT4. Tumor is fixed or invades adjacent structures other than seminal vesicles: 
external sphincter, rectum, levator muscles, and/or pelvic wall 
 
1
 Invasion into the prostatic apex or into (but not beyond) the prostate capsule is 
not classified as pT3, but as pT2. 
 
Based on large series, local cancers with <pT3 have a very favorable long-term 
prognosis in terms of cancer-specific mortality, comparable even to that of age-
matched controls (Zincke et al. 1994). Seminal vesicle invasion (pT3b) predicts 
early PSA progression (Waltz et al. 2009). 
If an iliac lymphadenectomy is performed pre-/intraoperatively, the pN stage can 
be assessed. Lymph node invasion (pN1) is predictive for early PSA recurrence 
following a radical prostatectomy (Waltz et al. 2009). The pathological (p)M 
category is seldom used because metastases are most often diagnosed clinically 
based on findings from bone scintigraphies and serum PSA values (Oesterling 1993, 
Montie 1995).  
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4.4.2 Surgical margin status 
A positive surgical margin status is a known risk factor for earlier PSA 
recurrence (Blute et al 1997, Swindle et al 2005, Vis et al 2006, Marks et al. 2007). 
It may also predict clinical recurrence of the disease and the development of distant 
metastases (Pfitzenmaier et al. 2008). Results regarding the prognostic significance 
of specific site of margin positivity (Blute et al. 1997, Vis et al. 2006) or the linear 
extent of margin positivity (Emerson et al. 2005, Vis et al 2006, Marks et al. 2007) 
remain controversial. Multiple positive sites or bilaterally positive surgical margins 
may indicate an earlier biochemical recurrence (Emerson et al. 2005, Somford et al. 
2011). Prognostic factors are closely associated with each other; it is not 
unexpected, therefore, that pre-treatment PSA values and Gleason scores are 
predictive of margin positivity (Somford et al. 2011). 
4.4.3 Capsular status 
The outer surface of the prostate consists of a layer of concentrically organized 
fibromuscular bands that are inseparable from the prostatic stroma. This 
fibromuscular band disappears at the apex (Ayala et al. 1989). Therefore, the 
prostate is considered to lack a true capsule. The fibromuscular band around the 
prostate, whether referred to as the capsule or pseudocapsule, is important to 
recognize because of its effects on pathological staging. Although it is somewhat 
controversial, the pathological stage pT3a is defined by the UICC as extracapsular 
extension (see above). Most pathologists would agree with a staging of pT3a when 
cancer infiltration is detected in the periprostatic fat but when less than half of the 
periprostatic surfaces harbor fat on the radical prostatectomy specimen, making the 
evaluation of extraprostatic extension unreliable (Hong et al. 2003). In needle 
biopsies, cancer infiltration into the fat is considered a reliable mark for stage pT3a, 
but intraprostatic fat may exist in up to 4% of prostates (Nazeer et al. 2009).  
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4.4.4 Prognostic groupings according to TNM stage, PSA value 
and Gleason score 
 
The prognosticators of prostate cancer can be used to create nomograms. Three 
of the strongest prognostic factors have been used in combination to create five 
prognostic categories (TABLE I) (Sobin et al. 2009). Patients with extraprostatic 
extension (pT3a-b) and patients with nodal or distant metastasis belong to a high-
risk category independent of PSA value or GS. However, most prostate cancers are 
multifocal and bilateral (pT2c) and belong to an intermediate risk category. 
Therefore, new strategies, including molecular biomarkers, have been developed to 
subdivide these patients into low- and high-risk groups. 
 
 
 
4.5 Prognostic findings from needle biopsy specimen 
In addition to the generally accepted prognostic factors for radical prostatectomy 
specimens, a large number of additional predictive and prognostic parameters are 
suggested for needle biopsies. Some of these factors are complex and are not used in 
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routine clinical work. Only the most important and clinically relevant prognostic 
factors are presented below. 
4.5.1 Number and length of biopsies 
The cancer detection rate depends on the total length of the biopsies (Iczkowski KA 
et al. 2002). Therefore, the length of the biopsies is one of the few prognostically 
significant parameters that can be influenced by education and by adapting special 
techniques (Bostwick et al. 2010). Increasing the number of the biopsy cores from 6 
biopsies to 10 or more has increased (up to 35%) cancer detection rates (Eskew et 
al. 1997, Eskicorapci et al. 2005, Elabbady and Khedr 2006). Moreover, objective 
methods for reporting the quality of the biopsies have been developed (Mondet et al. 
2009).  
 
4.5.2 Total percentage of cancer (TPC)  
The total percentage of cancer on the needle biopsies is predictive of a pT stage ≥3 
in the radical prostatectomy specimen and of biochemical recurrence following 
radical prostatectomy (Villamon-Fort et al. 2007, Brimo et al. 2008, Rajab et al. 
2010, Quintal et al 2011). 
4.5.3 Greatest percentage of cancer (GPC) 
The greatest percentage of cancer in a single biopsy core is associated with a pT 
stage ≥3 in the radical prostatectomy specimen (Brimo et al. 2008). This metric has 
also shown independent prognostic value in surgically treated patients (Nelson et al. 
2002). In recent comparisons of various morphometric measurements of prostate 
needle biopsy tissue, however, GPC was the only parameter not associated with 
PSA recurrence (Quintal et al 2011). 
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4.5.4 Percentage of cancer-positive cores (CPC) 
In the past, the use of systematic sextant biopsies for non-palpable tumors showed 
only a weak correlation between cancer-positive needle biopsy cores and findings 
from the prostatectomy specimen (Noguchi et al. 2001). More recently, both the 
number of cores positive for cancer and the percentage of cancer-positive cores have 
shown independent prognostic power (Winkler et al. 2004). In a study by San 
Francisco et al. (2004), the percentage of positive cores was a better predictor of 
cancer recurrence than the pre-treatment PSA value. Linear measurements of the 
cancer have been encouraged by other investigators (Haggarth et al. 2005). 
Recently, Rajab et al. (2010) has addressed this issue in a large study in which the 
percentage of cancer and the percentage of cancer-positive cores were independent 
prognostic factors, superior to the total length of the cancer (mm) and the number of 
cancer cores.  
4.5.5 Perineural invasion (PNI) 
Nerves are located near the capsular area of the prostate, and the most common 
spreading route for prostate cancer is capsular penetration into the perineural space 
(Villers et al. 1989). Perineural invasion (PNI) is a common event (approximately 
75%) in radical prostatectomy specimens (Maru et al. 2001) and therefore lacks 
prognostic significance (Merrilees et al. 2008). However, PNI detected in core 
biopsies is associated with adverse findings in the radical prostatectomy specimen 
(Loeb et al. 2009, Moussa et al. 2009) and is a significant prognostic factor in 
univariate analyses of surgically treated patients (Nelson et al. 2002). The presence 
of PNI also correlates with earlier PSA recurrence in patients treated with external 
beam radiotherapy (Bonin et al.1997, Yu et al. 2007).  
 
4.5.6 Worst (highest) Gleason score 
In the traditional Gleason scoring system used for needle biopsy specimens, only the 
predominant and second most common cancer patterns are considered. According to 
the modified Gleason scoring system established by the ISUP 2005 Consensus 
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Conference, the most aggressive cancer observed in the needle biopsies should be 
incorporated as the second pattern even if only present in small amounts (Epstein et 
al. 2005). In the case of individually embedded biopsies, each biopsy is given a 
separate Gleason score. The primary and secondary Gleason grades from the biopsy 
with the highest GS are used by clinicians in pre-treatment nomograms (Memorial 
Sloan-Kettering Cancer Center at 
http://www.mskcc.org/applications/nomograms/prostate/PreTreatment.aspx 
25.02.2011). 
In a few studies, the worst Gleason score showed a better correlation than the 
overall Gleason score to findings from subsequent radical prostatectomy specimens 
(Kunju et al. 2009, Kunz and Epstein 2003, Poulos et al. 2005). Furthermore, the 
length (mm) of the most aggressive cancer focus is predictive for biochemical 
(PSA) recurrence (Brimo et al. 2008). 
 
4.6 Prognostic molecular markers 
There is an ongoing, vigorous search for new molecular and genetic markers for 
prostate cancer. The main pathways under investigation, including cell cycle 
control, androgen receptor signaling, genomic instability, adhesion molecules, death 
and apoptosis, signal transduction and angiogenesis, are extensively reviewed by 
Quinn et al. (2005) and Buhmeida et al. (2006). Some of the most studied single 
biomarkers with potential clinical relevance are presented in TABLE II. Recently, a 
promising genetic approach utilizing a tumor-derived RNA expression signature of 
multiple (n=31) cell cycle progression-related genes was developed (Cuzick et al. 
2011). The authors concluded that the cell cycle progression signature is a robust 
prognostic marker that may have an essential role in treatment decisions following 
additional validation. The following chapters concentrate on the biomarkers used in 
studies I and III. 
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4.6.1 BAX 
Cell cycle-arresting tumor suppressor genes and apoptosis-regulating genes are 
important in the pathogenesis of prostate cancer (Visakorpi et al. 1992, Haussler et 
al. 1999). BAX is a soluble cytoplasmic protein that upon induction of apoptosis 
locates to the outer mitochondrial membrane (Wolter et al. 1997). There it forms 
homodimers and higher-form oligomers that resemble pores, resulting in altered 
permeability of the outer mitochondrial membrane (Dewson and Kluck 2009). This 
phase of apoptosis is referred to as the “point-of-no-return”, meaning an irreversible 
cascade of proteolytic events and damaged mitochondrial function. Previously, 
BAX overexpression was been reported in almost all prostate cancers (Krajewska et 
al. 1996, Johnson et al. 1998). BAX expression is also a common finding in low-
grade prostatic intraepithelial neoplasia (LGPIN) and HGPINs (Johnson et al.1998). 
Apoptosis is a complex process, and there is a delicate balance between pro-
apoptotic and anti-apoptotic proteins. For example, in a study by Mackey et al. 
(1998), BAX expression was not predictive as an individual factor, but an increased 
BCL-2/BAX ratio was associated with a poor response to radiotherapy.  
4.6.2 BCL-2 
The pro-apoptotic function of homodimerized BAX complexes may be suppressed 
by BCL-2, which interferes by forming heterodimers with BAX (Oltvai et al. 1993). 
Increased expression of BCL-2 has been reported in both LGPIN and HGPIN 
(Baltaci et al. 2000, Haussler et al. 1999), which are considered the most likely 
precursors of prostate cancer (Haggman et al. 1997, Bostwick et al. 1999, Srigley et 
al. 2010). The expression frequency of BCL-2 in PIN is approximately tenfold 
higher than expression in prostate cancers (Johnson et al. 1998). BCL-2 has been 
reported to be expressed more frequently in high-grade tumors by some authors 
(Krajewska et al. 1996, Stattin et al. 1996), whereas others have found no 
correlation between BCL-2 expression and tumor grade (Karaburun Paker et al. 
2001). Upregulation of BCL-2 is a late step in cancer progression (Furuya et al. 
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1996). Overexpression of BCL-2 is associated with the transition to androgen-
independent prostate cancer and poor prognosis (McDonnell et al. 1992). Increased 
BCL-2 expression has been noted in nodal metastases in some studies (Krajewska et 
al. 1996) but not in others (Tu 1996).  
 
4.6.3 EZH2 
Enhancer of zeste homolog 2 (EZH2) is a highly evolutionary conserved 
epigenetic regulator that functions as a histone methyltransferase (Simon et al. 
2008). Overexpression of EZH2 has been observed in several cancers, including oral 
squamous cell carcinomas (Kidani et al. 2009), hepatocellular carcinoma (Sudo et 
al. 2005), gastric cancer (Matsukawa et al. 2006), urothelial carcinoma of the 
bladder (Raman et al. 2005), and prostate carcinoma (Varambally et al. 2002). 
EZH2 overexpression shown to have independent prognostic value in surgically 
treated patients (Laitinen et al. 2008). In addition, the gene encoding EZH2 is 
amplified in late-stage prostate cancer (Saramäki et al. 2006). One of the 
mechanisms by which EZH2 is believed to mediate prostate cancer aggressiveness 
is by transcriptional silencing of the tumor suppressor gene E-cadherin (Cao et al. 
2008). 
4.6.4 Ki-67 
Ki-67 (also known as MIB-1) is one of the most extensively studied prognostic 
proliferation markers. It is expressed in all phases of the cell cycle in proliferating 
cells but not in non-dividing cells (Guillaud et al. 1989, Gerdes et al. 1991). The Ki-
67 labeling index is associated with Gleason grade and independently predicts 
distant metastasis and cancer-related deaths (Bubendorf et al. 1998, Pollack et al. 
2004). Ki-67 is an independent prognosticator in preoperative biopsies with small 
volumes and cancers with low Gleason score (Zellweger et al. 2009). Alternatively, 
a very low Ki-67 labeling index in radical prostatectomy specimens is correlated 
with a positive prognosis (Laitinen et al. 2008). In contrast to assessing Gleason 
patterns, the cell proliferation fraction as measured by Ki-67 is characterized by 
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minimal inter-observer variability (Gunia et al. 2008). Moreover, there are simple 
and rapid digital image analysis tools available to reliably measure the Ki-67 index 
(Tuominen et al. 2010).  
4.6.5 MCM7 
Minichromosome maintenance protein 7 (MCM7) is a critical component of the 
DNA replication licensing complex (Shi et al. 2008, Ren et al. 2006). In prostate 
cancer, proliferative indexes measured by Ki-67 are relatively low when compared 
to MCM7. This latter marker may therefore act as a better prognostic factor 
(Badmanabhan et al. 2004). In addition, the gene encoding MCM7 is amplified and 
overexpressed during prostate cancer progression (Shi et al. 2008, Ren et al. 2006). 
In our earlier study of prostatectomy-treated patients, MCM7 was a strong 
prognostic marker, especially in combination with EZH2 (Laitinen et al. 2008).  
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AIMS OF THE STUDY 
The trend toward smaller cancers presents a great diagnostic challenge for 
pathologists. It is well known that focal cancers restricted to a single needle biopsy 
usually indicate larger, bilateral and/or multifocal cancers in the subsequent radical 
prostatectomy specimen (Boccon-Gibod et al. 2005, Montanari et al. 2009). All 
diagnostic cancerous foci should be detected and reported for two reasons. First, the 
treatment of focal cancer in the needle biopsies may differ from that of multifocal 
cancers, and second, the percentage of positive cores can be used as a prognostic 
parameter (Winkler et al. 2004, Rajab et al. 2010).  
The expression levels of apoptosis-controlling factors in benign, pre-malignant 
and malignant epithelium, are analyzed as possible mechanisms of multifocality in 
study I. Diagnostic issues and suggested resolutions associated with both small 
atypical foci and the risk of overlooking minute cancers are addressed in study II. 
Prognostic parameters, with an emphasis on the modified Gleason scoring system, 
are analyzed in detail in studies III and IV.  
 
The specific aims of the present study were: 
 To compare the expression of the apoptosis-regulating proteins BAX and 
BCL-2 in morphologically normal areas of benign and cancerous 
prostates 
 To study the sensitivity and feasibility of routine dual-color, three-
antibody immunostaining in detecting and characterizing small atypical 
lesions and cancers from interval sections of needle biopsies 
 To evaluate prognostic histopathological parameters from needle biopsies 
of endocrine-treated patients 
 To analyze the prognostic value of the promising molecular biomarkers 
EZH2, Ki-67 and MCM7 with computer-aided digital image analysis 
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 To compare the prognostic values of different Gleason grading methods 
as determined from pooled needle biopsies 
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MATERIALS AND METHODS 
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1. Tissue samples 
All the studies were approved by the National Authority for Medicolegal Affairs 
(permission 3896/32/300/02) and/or the Ethical Committee of Tampere University 
Hospital (TAUH) (permission R03203). 
1.1 Study I 
  
Cancer tissues were obtained from radical prostatectomies carried out at Tampere 
University Hospital in 1999 (n=33). Hyperplastic prostatic tissue was obtained 
from transurethral resection chips (n=9), and control tissue was obtained from 
autopsies of men aged 24, 26 and 47 years with no known prostatic disease 
(n=3). Autopsies were performed within 24 hours of death. Radical 
prostatectomy and autopsy specimens were completely embedded into micro- 
and macro-blocks. They were then cut and stained with H&E according to the 
normal histopathological process of Laboratory Center, Tampere University 
Hospital. A total of 1182 foci, including those diagnosed as benign, BPH, 
LGPIN, HGPIN, adenocarcinoma of various Gleason grades, and perineural 
invasion, were selected from H&E-stained slides and marked with a permanent 
pen. Selected foci were punched with a 2 mm needle and transferred to 45 tissue 
microarrays (TMA) (Kallioniemi et al. 2001). An individual heterogenic TMA 
was generated for each patient. The number of foci per individual TMA varied 
between 14 and 53. Benign areas were selected away from the cancer. TURP 
specimens were punched from the middle of the resected chips to avoid 
coagulation artifacts. TMAs containing 1182 different foci were immunostained 
with BAX and BCL-2. In addition, one H&E stain was performed for each TMA 
to confirm that the samples were representative.  
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1.2 Study II 
 
Tissue was prospectively collected from 1000 consecutive patients who 
underwent a clinical prostate needle biopsy in the TAUH district between 2007 and 
2009. Biopsies from the right and left lobes of the prostate (six tissue cores each) 
were formalin-fixed and paraffin-embedded into two separate blocks. Biopsies were 
step-sectioned at six levels in the Department of Pathology of TAUH according to 
normal protocols. The tissue located between the six routine sections was cut (at 
five levels), collected and stored at -70 °C for research purposes. For this study, 
stored interval sections of 200 patients were randomly chosen from among the 1000 
consecutive patients. One interval section was used for H&E staining, and an 
adjacent section was used for 2IHC. This protocol ensured the maximal preservation 
of similar morphology on the stainings. 
 
1.3 Studies III and IV 
 
Approximately 1200 new patients were diagnosed with prostate cancer between 
1999 and 2003 in the TAUH district. Of these, approximately 25% were primarily 
endocrine-treated. Patients had metastatic disease, were not suitable for radical 
treatment due to their general condition, or presented with low-grade cancer but 
wanted to have active treatment instead of active surveillance. Three cases 
diagnosed from TURP were excluded, and the resulting study cohort consisted of 
295 consecutive, endocrine-treated patients. Original H&E-stained slides and/or 
paraffin-embedded specimens were available from 247 cases for study III, and 236 
cases were available for study IV. Biochemical progression was the endpoint and 
defined as a ≥ 25% rise in PSA with a PSA value ≥ 2.0 ng/ml above the nadir in two 
consecutive measurements, as recommended by The Prostate Cancer Clinical Trials 
Working Group (PCWG2) guidelines (Scher et al. 2008). One pathologist (T. T. T.) 
re-evaluated biopsies for histopathological volume estimates and modified Gleason 
scores according to ISUP 2005 Consensus Conference guidelines. Bone 
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scintigraphy was performed in all symptomatic patients and in asymptomatic 
patients when the PSA was ≥20 ng/ml or aggressive (original compound GS >7) 
prostate cancer was present (Lee et al. 2000).  
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2. Immunohistochemistry 
2.1 BAX and BCL-2 (I) 
Four-micron sections of TMAs were sectioned and transferred to SuperFrost Plus 
glass slides. Immunohistochemical stainings were performed using a Techmate 
staining automat. The antibodies used were polyclonal rabbit anti-human BAX 
(PharMingen Europe, Hamburg, Germany) at a dilution of 1:1000 and monoclonal 
anti-human BCL-2 oncoprotein clone 124 (Dako, Glostrup, Denmark) at a dilution 
of 1:60. Antibodies were visualized with the DAB-brown reaction. The slides were 
lightly counterstained with hematoxylin. 
2.2 EZH2, MCM7 and Ki-67 (II) 
Immunostainings were performed with antibodies against Ki-67 (MM1, 
NovocastraTM Laboratories Ltd., Newcastle Upon Tyne, United Kingdom), EZH2 
(NCL-L-EZH2, clone 6A1, NovocastraTM Laboratories Ltd., Newcastle Upon 
Tyne, United Kingdom), and MCM7 (sc-9966, Santa Cruz Biotechnology, Inc., CA) 
with Power Vision1TM Poly-HRP Histostaining Kit (ImmunoVision Technologies 
Co, Daly City, CA) according to the manufacturers’ instructions. The stainings were 
performed with an Autostainer 480 (Lab Vision Corp, Fremont, California, USA). 
Briefly, the slides were autoclaved in pretreatment buffer (5 mM Tris-HCl/1 mM 
EDTA, pH 9) at 121°C for 2 min, followed by overnight incubation with the 
primary antibody diluted in pre-block solution (Ki-67 1:1,500, EZH2 1:300, MCM7 
1:500). After washing and blocking, the bound primary antibody was visualized 
with the PowerVisionTM Poly-HRP IHC Detection Kit (ImmunoVision 
Technologies Corporation, Brisbane, CA). The slides were counterstained with 
hematoxylin. 
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2.3 Dual-color, three-antibody immunostaining with 
AMACR, p63 and CK34betaE12 (III) 
Four-micron sections were cut and transferred to SuperFrost Plus glass slides. The 
slides were deparaffinized using hexane and absolute ethanol (2 x 2 minutes + 1 
minute) and heat-treated in 0.01 M Tris-HCl EDTA (pH 9.0) at 121°C for 2 minutes 
using PickCell Antigen Retriever (PickCell Laboratories, Lelystad, Netherlands). 
The slides were stained using a LabVision Autostainer (LabVision, Fremont, CA). 
A cocktail of two mouse monoclonal antibodies against the basal cell layer, p63 Ab-
4 at 1:200 (NeoMarkers, Fremont, CA) and CK-HMW Ab-3 (34betaE12) at 1:100 
(NeoMarkers, Fremont, CA), and a rabbit monoclonal antibody against AMACR 
(clone 13H4) at 1:100 (Dako, Copenhagen, Denmark) was mixed and applied to 
tissue sections for 30 minutes at room temperature. After two buffer rinses, a 
mixture of anti-rabbit alkaline phosphatase and anti-mouse horseradish peroxidase 
conjugates (polymer-based secondary antibodies, Multivision kit, LabVision) were 
applied for 20 minutes. The peroxidase reaction was developed by first using 
diaminobenzidine (DAB) for 5 minutes followed by a rinse and exposure to an 
alkaline phosphatase substrate (HistoBlue, Multivision kit). In initial staining tests, 
red chromogen (Vector Red, Vector Labs, Burlingame, CA) was tested instead of 
HistoBlue. Following the chromogen reactions, the slides were rinsed in distilled 
water, counterstained with hematoxylin, and rinsed again. The slides were allowed 
to air dry and were coverslipped with a permanent mounting medium. 
2.4 Microscopic evaluation of samples 
2.4.1 Study I 
The accuracy of the sampling was confirmed using one H&E-stained slide from 
each TMA. The TMA slides consisted of spots in rows representing benign, BPH, 
PIN, various grades of cancer, and foci of capsular PNI (one row for each 
histological type). Foci containing atrophy or inflammation or otherwise not 
representing the desired histology were omitted from the data analysis.  
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2.4.2 Study II 
All slides were evaluated by one pathologist (T. T. T.) using an Olympus BX41 
light microscope. The first evaluation was conducted using one H&E-stained 
interval section from each block. Histopathological diagnoses were restricted to 
benign, HGPIN, ASAP, or adenocarcinoma. Indications for further immunostains 
and a Gleason score (for adenocarcinomas) were recorded. Cases in which IHC was 
deemed necessary were then evaluated using 2IHC and H&E-stained sections. 
Simultaneous evaluation of the interval sections of tissue stained by 2IHC and 
H&E-stained interval sections from all blocks were performed one month later. 
Prior to the evaluation, the slides were randomly rearranged to hamper visual 
memory. In this setting, the 2IHC slides were first screened briefly using 4 x – 10 x  
objective lenses. The final diagnosis was assessed following evaluation of both the 
2IHC and H&E-stained slides. The time required to complete the histopathological 
assessment was recorded for each slide. Discrepancies between these analyses and 
the original pathology reports were reviewed by five pathologists. A consensus was 
considered reached when 4 of 5 pathologists independently reached the same 
diagnosis. 
2.4.3 Studies III and IV 
Two slides from each patient were analyzed. The most representative H&E-
stained slide, consisting of biopsies from the left or right lobe, was selected and 
scanned with Aperio ScanScope® XT (software version 9; Aperio Technologies, 
USA) and viewed in JPEG2000 using JVSview virtual microscopy software version 
1.2 (Tuominen and Isola 2009). Virtual microscopy can be reliably applied to 
scoring prostate needle biopsies and has a strong concordance with Gleason grading 
(Helin et al. 2005).  
The total percentage of cancer was derived from the original pathology report 
based on the bilateral evaluation. The greatest percentage of cancer was estimated as 
the proportional lengths of cancer of the total core length. The diameter of the PNI 
was measured from a digital image using ImageJ scale and measuring tools. 
The worst (WGS) and overall (OGS) Gleason scores were evaluated according to 
the recommendations of the International Society of Urological Pathologists, 2005. 
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The OGS was derived as a sum of the predominant and most aggressive (or 
secondary) patterns of all biopsy cores, treated as one long core. The WGS in a 
single biopsy core was assessed in cases in which one biopsy contained a higher 
Gleason grade (e.g., 4+4 cancer) and other cores a lower grade (e.g., 3+4). In cases 
in which all positive biopsy cores contained the same Gleason grade (e.g., 3+3) or 
there was only one core positive for cancer, the WGS was equal to the OGS. A 
Gleason score of 7 was considered as two separate grades (e.g., the WGS could 
equal 4+3 and the OGS 3+4). Compound Gleason scores (CGS) were obtained from 
the original pathology reports from 1999-2003 such that Gleason grades were also 
assessed according to the recommendations prior to the refinement suggested by the 
ISUP 2005 Consensus Conference. The predominant the secondary Gleason patterns 
were estimated from two slides containing six pooled needle biopsy specimens from 
the right and left sides. 
 
2.5 Interpretation of immunostainings (I-III) 
2.5.1 BAX and BCL-2 
Semiquantitative staining indices were determined for each focus by estimating the 
staining intensity (range 0-3) and multiplying it by the approximate percentage of 
stained epithelial cells. This method gave a staining index ranging from 0 to 300. 
Basal cells and luminal epithelial cells were scored as different entities. Areas with 
acute and/or chronic inflammation were excluded. 
2.5.2 2IHC 
Dual-color immunostainings were interpreted under an Olympus BX41 light 
microscope following inspection of both 2IHC- and H&E-stained slides, keeping 
diagnostic pitfalls in mind. 
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2.5.3 EZH2, Ki-67 and MCM7 
 
The digitalization of the immunostained slides was performed using a Aperio slide 
scanner. Three hotspot areas showing the highest immunostaining were selected on 
a virtual microscope. Screenshots of the hotspots were captured from each slide and 
transferred to ImageJ, which is open access software for the analysis and processing 
of digital images (Collins 2007). Images were analyzed with ImmunoRatio, an 
analysis tool developed for analyzing nuclear immunostainings in hematoxylin-
counterstained tissue sections (Tuominen VJ et al. 2010). Analysis was based on 
color deconvolution to separate the staining components (i.e., DAB brown and 
hematoxylin blue), and adaptive thresholding was used to define staining positivity. 
The proportion (%) of the brown-stained area over the sum of brown- and blue-
stained areas was defined as the labeling index. Results of the automated analysis 
were verified by one pathologist (T. T. T.), who compared the original image to the 
segmented image. 
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3. Statistical analyses (I-IV) 
3.1 Study I 
Basic characteristics of the staining indices were examined by cross-tabulation. A 
linear mixed-models analysis, in which staining indices were considered continuous, 
was used in paired comparisons between all morphological categories. The BAX 
and BCL-2 staining indices were considered dependent variables; morphological 
classification was the explanatory variable. The data were fitted to a random-effects 
model with individual patients as the random effect. To further analyze 
immunoreactivity in controls, tissue from patients with BPH and normal epithelia 
from prostate cancer patients (CaNE) were examined. For these analyses, we used a 
chi-squared test, in which the staining indices were dichotomized using a value of 
50 as a cut-off point between negative and positive. A P-value 0.05 was considered 
the limit of statistical significance. Statistical analyses were performed using SPSS 
versions 11.0 and 11.5 and SAS version 8.1.  
 
3.2 Study II 
The Wilcoxon signed rank test was used for paired comparisons between the 
intraobserver settings to evaluate statistical differences in the time required to 
complete the histopathological assessments. Statistical analyses were performed 
with GraphPad Prism version 4.00. In addition, reproducibility of Gleason scoring 
was manually analyzed using the kappa method.  
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3.3 Study III 
Fisher’s exact, chi-squared and one-way ANOVA tests were used to evaluate 
associations between the variables. Survival analysis was performed using the 
Kaplan–Meier method, and the statistical significance of survival differences 
between patient groups was determined using the Mantel–Cox test. Univariate and 
multivariate Cox regression analyses were performed to calculate the relative risk 
estimates (RR) and to evaluate the independence of the prognostic markers. 
Statistical analyses were performed with BMDP. 
 
3.4 Study IV 
The agreement between Gleason scoring methods was analyzed with the κ-
coefficient method. Survival analyses were performed using the Kaplan–Meier 
method, and the statistical significance of survival differences between patient 
groups was determined with a Mantel-Cox (log-rank) test. Univariate and 
multivariate Cox regression analyses were performed to calculate the relative risk 
estimates (RR) and to evaluate the independence of the prognostic grading methods. 
Statistical analyses were performed with BMDP. 
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RESULTS 
69 
1. Expression of apoptosis regulators 
in heterogenic TMAs (I) 
1.1 BAX 
In autopsy samples from normal (control) prostates, no BAX expression was 
observed on the luminal epithelium. However, BAX was expressed in basal cells, 
thus serving as an intrinsic staining control. Normal luminal epithelium showed 
elevated BAX expression in 16.3% of cancerous prostates and in 3.9% of BPH cases 
(p<0.001). In paired comparisons, BAX expression was significantly lower in 
adenocarcinomas of Gleason grade 2 than in Gleason grades 3-5 (p<0.001). Both the 
staining index estimate of BAX expression (mean 127, 95% confidence interval 
120-134) and the number of BAX-positive foci (91%) were significantly higher in 
PNIs than that in any other group (p<0.001 to p<0.009). In conclusion, BAX 
expression showed nearly steadily increasing staining indices from benign luminal 
epithelium to more aggressive patterns of cancer and PNI. 
1.2 BCL-2 
In contrast to the lack of BCL-2 expression in control prostates, the normal 
epithelium of cancerous prostates showed elevated BCL-2 expression in 6.9% of 
foci (p=0.004). BCL-2 expression was most frequent in foci with LGPIN (35%) and 
HGPIN (24%). In well-differentiated cancers of Gleason grades 2 and 3, BCL-2 
expression was virtually absent. However, BCL-2 expression was detected in 
approximately 13% of high-grade cancers of Gleason grades 4 and 5 and in 
approximately 12% of foci with perineurally growing cancer. 
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2. Dual-color immunostaining in 
detecting small cancers (II) 
Our initial staining tests included dual-color stainings with brown-blue and brown-
red combinations and conventional single-chromogen DAB-brown immunostaining 
reactions for AMACR. Both dual-color stainings showed satisfactory results. 
However, because brown-blue was considered easy to interpret and because color 
deconvolution of brown-red digital images could be more difficult, the former was 
chosen for this study. Examples of the stainings are presented in Figure 12. 
 
 
Figure 12. An example of a small focus containing poorly differentiated adenocarcinoma of 
GS 4+4=8. The sample shows fusion of glands and infiltrative growth between obviously 
benign glands. A) Cancer is readily detectable in the H&E staining. B) Single-chromogen 
immunostaining against AMACR (DAB-brown). C) Three-chromogen immunostainings 
against basal cells (p63 and CK34betaE12) and AMACR. Basal cells visualized with DAB-
brown and AMACR with HistoBlue. D) Same as C except that HistoBlue is substituted for 
Vector Red. (100 x). 
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2.1 Increased sensitivity 
Of the 200 randomly selected patients, adenocarcinoma was diagnosed in 87 (43%) 
patients in the original pathology reports. H&E and occasionally immunostainings 
(on request) were used for these diagnoses. Of the 113 cases diagnosed as non-
malignant, 14 additional putative cancers were identified from interval sections with 
the aid of routine 2IHC by one pathologist (T. T. T.). Interval sections from 14 
cases, including one H&E staining and one 2IHC, were then independently 
reviewed by five pathologists. Retrospective re-evaluation yielded 8 additional 
consensus diagnoses of adenocarcinoma and one ASAP. In 5 cases, a consensus was 
not reached. Six of the eight consensus cancers were well-differentiated (GS 
3+3=6), while two (25%) were graded GS 4+4=8.   
2.2 Feasibility analysis 
The amount of time spent on the microscopic assessment of H&E and 2IHC 
(average 251 sec.) staining was shorter than for H&E followed by 2IHC on request 
(average 299 sec., p<0.0001). The microscopic assessment of H&E and 2IHC was 
faster than for H&E because the risk of overlooking small atypical lesions on 2IHC 
was considered smaller. Although the evaluation of the biopsies was faster, more 
lesions were found, and a good reproducibility of Gleason scores was achieved, with 
a kappa-value of 0.72. 
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3. Prognosticators in the needle 
biopsies of hormone-treated 
patients (III and IV) 
3.1 Basic characteristics of the studied patients 
The median age of the patients at the time of diagnosis was 73.6 years (range 
52.7-88.8 years). The median follow-up time was 56.5 months (range 8-104 
months). The median pre-treatment PSA value was 16.5 ng/ml (range 1.9-10750 
ng/ml). Over half (54.9%, 162/295) of patients had localized disease (cT1-T2). One 
third of patients (33.6%) experienced PSA progression. Cancer-specific mortality 
was 6.4% (19/295), and deaths due to other reasons occurred in 25.7% of patients 
(76/295). The distribution of primary hormonal treatments was the following: 
LHRH analog (n=208); surgical castration (n=55); antiandrogen bicalutamide 
(n=27); and maximal androgen blockade (n=3).   
3.2 Histopathological parameters and proliferation 
markers (III) 
All tumor histopathologic parameters were significantly associated with 
progression-free survival based on univariate analyses (TABLE III). Of these, the 
percentage of cancer-positive cores showed the strongest prognostic value, with a 
relative risk of 3.2 (95% confidence interval 1.9-5.2). The only histopathological 
parameter not associated with progression was the diameter of the greatest nerve 
showing PNI (p=0.75). All immunohistochemical proliferation markers were also 
significant prognosticators based on univariate analyses (TABLE III). 
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In a first multivariate analysis of the 12 parameters shown in TABLE III 
(reclassified GS excluded), four independent prognostic markers were identified: 
• Pre-treatment PSA level (2.6, 1.3-4.9) 
• Gleason score (2.1, 1.4-3.2) 
• Perineural invasion (1.6, 1.2-2.2) 
• Clinical T stage (2.0, 1.1-3.9) 
 
Because samples with GS 3+4=7 and GS 4+3=7 had clearly different prognoses, 
a second multivariate analysis was performed with the non-conventional, 
“reclassified” Gleason score groups 5-7(3+4), 7(4+3)-8, and 9-10. The same four 
prognosticators were identified in the second multivariate analysis, with the 
Gleason score now being the strongest prognostic factor: 
• Gleason score (2.2, 1.5-3.2) 
• PSA level (2.1, 1.1-4.2) 
• PNI (1.6, 1.2-2.2) 
• Clinical T stage (1.9, 1.0-3.7) 
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To further evaluate the prognostic abilities of the markers, various models that 
included the four independent factors were created and tested with different cut-off 
values for Gleason scores. Combinations of the independent markers (PSA>20 or 
GS≥4+3 or PNI>3 or cT>2) yielded the best risk stratification (RR 11.6, 10.4-12.7). 
Patients with >3 foci with PNI were at high risk for early progression. Within the 
subgroup of patients with Gleason score 7, the progression-free time for patients 
with Gleason grading 4+3 was significantly shorter than for patients with grading 
3+4 (p=0.013). In the same patient group, Ki-67 expression with a cut-off value of 
10% was highly capable of identifying patients with early PSA recurrence 
(p<0.0001). 
 
3.3 Comparison of prognostic abilities of worst and 
overall (modified) Gleason scores (IV) 
 
The average number of core biopsies from one lobe was 4.5 (median 4, range 1-9), 
and the average number of positive biopsy sites was 3.1 (median 3, range 1-7). The 
number of cases with multiple positive biopsy sites was 191.  
A clear trend towards higher Gleason sums was noted from compound Gleason 
score (CGS) to OGS and from OGS to WGS. In the original pathology reports from 
1999-2003, CGS of ≤5 were assessed in 22 patients. With the same needle biopsy 
material but using the modified Gleason score system, WGS=5 and OGS=5 was 
assessed in only four patients, and no patients had a GS below 5.  
The WGS was higher than the OGS in 43 (18%) cases. In 14 of 65 cases with 
OGS=7, at least one biopsy core containing higher-grade cancer (WGS 4+4=8) was 
found. In 12 of 39 cases with OGS 3+4=7, the biopsy core containing the highest 
Gleason score yielded WGS 4+3. The difference between WGS and OGS was 2 in 
three cases. In all of these cases, the OGS was 8 (3+5 or 5+3), and the WGS was 10 
(5+5). The agreement between the WGS and OGS was high (κ-coefficient=0.82). 
When compared with the original CGS, which was obtained using pathology reports 
generated before the refined guidelines, a significantly lower concordance was 
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found between the WGS and the CGS (κ=0.48) and between the OGS and the CGS 
(κ=0.44).  
Univariate analyses of OGS and WGS yielded similar RRs. Re-classification of the 
Gleason score groups to <7(4+3), 7(4+3)-8, and 9-10 slightly improved the 
prognostic value of both the WGS and OGS. In multivariate analyses of the six 
different Gleason grading methods, reclassification of the OGS as <7(4+3), 7(4+3)-
8, and 9-10 was the strongest (and only) independent prognostic factor (RR 2.6, 
95%-confidence interval 2.0-3.5).  
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DISCUSSION 
Pathology has a long tradition on analyzing thin-cut histochemically-stained 
tissues under a light microscope. During the last two decades, the significance of 
immunohistochemistry has increased and broadened the search for new diagnostic 
and prognostic tools for use in pathology. In the histopathology of the prostate 
gland, there are several diagnostic pitfalls to keep in mind. For instance, pre-
malignant lesions and adenocarcinoma must be distinguished from benign glands, 
AAH, atrophy, and seminal vesicle epithelium. Immunohistochemistry has proven 
to be an invaluable tool in aiding differential diagnostics. However, a qualified 
laboratory process with strong reproducibility is required for reliable interpretation 
of the immunostainings. 
Digitalized images of immunostainings have enabled the development of 
automated image analysis tools, which can yield better objectivity and 
reproducibility. Microscopic assessments of tissue histology are important parts of 
all immunohistochemical studies because tissues are visually chosen for analysis. In 
addition, correct interpretation of the results of automated analysis also requires 
comparisons of the morphologies of different stainings. All of the studies presented 
here combined detailed, “old-fashioned” histopathological assessment with more 
modern tools, including automated image analyses, immunohistochemical stainings 
and virtual microscopy.  
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1. Androgens, apoptosis and field 
effect (I) 
The prostate and seminal vesicles are accessory reproductive glands, located 
adjacent to one another, but are still quite different in terms of malignant potential. 
The former suffers from multifocal cancers with extremely high incidence, while 
there have been only approximately 50 case reports of primary carcinomas reported 
world-wide for the latter (Thiel and Effert 2002). The reason behind this 
phenomenon is incompletely understood. Development of the normal prostate and 
prostate cancer is regulated by androgens (Isaacs et al. 1992), and androgen 
deprivation (including finasteride) induces apoptosis of prostatic epithelial cells 
(Kyprianou et al. 1990, Golbano et al. 2008). However, castration induces apoptosis 
in the seminal vesicle epithelium in a similar manner (Tanji et al. 2003).  
We studied apoptosis as one possible mechanism underlying the multifocality of 
prostate cancer. The key apoptotic regulators BAX and BCL-2 showed increased 
expression in some foci of normal epithelium of cancerous prostates, suggesting 
altered apoptotic control. These immunohistochemical changes may represent the 
very early phase of the multifocal carcinogenetic process. The concept of the field 
effect, also termed field cancerization, was introduced in the 1950s. At this time, 
authors noted that microscopic abnormalities in grossly benign tissues were 
associated with an abnormally high risk of a recurrence of multifocal oral squamous 
cancer (Slaughter et al. 1953). The concept of the field effect has extended through 
the development of molecular biomarkers, including GSTP1, APC and RARb2 
(Chai and Brown 2009). To date, abnormal expression of such field effect 
biomarkers in normal tissues have been reported in various organs, including the 
prostate (Nonn et al. 2009). In addition, invasive cancer communicates with its 
environment, the stroma, leaving detectable molecular fingerprints (Halin et al. 
2010). In our study, benign foci of cancerous prostates in TMAs were consciously 
sampled away from the cancer. Thus, the observed changes in apoptotic regulation 
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are more likely to represent the field effect than tumor-induced secondary changes 
and may explain the multifocal origin of prostate cancer.  
Most newly detected prostate cancers in the future will have a small volume and 
therefore will not always be observed with the current diagnostics based on needle 
biopsies. The tissue adjacent to cancer has been shown to harbor morphological or 
genetic changes (Malins et al. 2004, Risk et al. 2010). Additionally, cancer can 
induce detectable changes to its environment to grow and invade (Halin et al. 2010). 
For these reasons, benign tissue surrounding the tumor has recently earned interest 
as a potential diagnostic and/or prognostic source of biomarkers (Halin et al. 2010). 
The concept of tumor-indicating normal tissue, resulting from secondary responses 
of the microenvironment, is a rather new subject (Halin et al. 2010) and needs to be 
distinguished from the carcinogenic field effect (Nonn et al. 2009), which is more 
likely to represent a primary change underlying prostate cancer multifocality. 
Secondary responses adjacent to the cancer could be most useful in the context of 
diagnostics, while biomarkers associated with the field effect could be useful in 
terms of cancer prevention, surgical considerations and prognosis (Chao and Brown 
2009). Clinical applications are awaited. 
The speed of tumor growth is dependent on the proliferation rate and average 
lifetime of the cancer cells (Isaacs et al. 1992). Cell proliferation rates increase in 
more aggressive prostate cancer phenotypes (Häussler et al. 1999). According to our 
results, apoptotic control is likely to be involved in and modulated during local 
progression of prostate cancer. Furthermore, our results demonstrate that the ratio of 
pro- to anti-apoptotic proteins is variable in different steps of progression. BCL-2 
expression has been noted in 35% of HGPIN cases, in 2-25% of prostate cancers 
(with a higher tendency in high-grade cancers), and in 38% of nodal metastases of 
prostate cancer (Krajewska et al. 1996, Johnson et al. 1998, Häussler et al. 1999). 
Moreover, concomitant upregulation of other anti-apoptotic proteins, such as 
members of the inhibitor of apoptosis (IAP) protein family, occurs early in the 
development of prostate cancer (Krajewska et al. 2003). In our study, BCL-2 
expression was noted in the premalignant lesions of LGPIN (35%) and HGPIN 
(24%) samples. Low-grade tumors were completely negative for BCL-2, but 
expression was apparent in approximately 12-13% of high-grade cancers (GS≥8) 
and in PNIs. Moreover, BAX expression was highest in foci with PNI. Prostate 
cancers not only express neurotrophins and their receptors but also can induce 
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neural growth, neurogenesis and axonogenesis (Ayala et al. 2008). Increased 
proliferation rates together with reduced apoptotic indices have been noted in PNI 
(Yang et al. 1996). Apparently, the effect of pro-apoptotic BAX is overridden by 
multiple mechanisms in PNI foci. 
Prostate cancer can eventually escape androgen-regulated apoptotic control. Various 
mechanisms in the transition to hormone-refractory disease have been demonstrated, 
including the amplification of androgen receptor (AR), AR mutations, and the 
induction of neuronal apoptosis inhibitory protein (NAIP) by androgen deprivation 
(Visakorpi et al. 1995, Linja et al. 2001, Haapala et al. 2007, Chiu et al. 2010). To 
date, there are no efficient treatment options for CRPC. 
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2. Diagnostic immunohistochemical 
markers (II) 
PSA screening can detect smaller and better-differentiated cancers (Laurila et al. 
2009, Cremers et al. 2010). The consequences of our results demonstrating the 
increased sensitivity of 2IHC in detecting small cancers from needle biopsies are 
difficult to estimate. Even the definition of minute cancer is difficult, resulting in 
interobserver variation among uropathologists (Van Der Kwast et al. 2010). In a 
study by Wolters et al. (2010), a diagnostic delay of four years did not the affect 
patient prognosis. Furthermore, preliminary results of active surveillance show that 
well-differentiated small-foci prostate cancers have a favorable prognosis and that 
intervention is rarely needed (Klotz et al. 2006). Although most of the additionally 
detected small cancers may be clinically insignificant, patients need to be monitored 
frequently, keeping in mind that most cancers are bilateral and multifocal (Boccon-
Gibod et al. 2005, Montanari et al. 2009). In our study, comparing routine 2IHC and 
clinical reports, two of eight of cancers detected with the aid of 2IHC were high-
grade (GS 4+4=8). In addition, two cases (1%) of high-grade adenocarcinoma were 
overlooked by one pathologist (T. T. T.) on the first examination with one H&E 
staining and one optional 2IHC slide compared to the routine 2IHC + H&E 
protocol. In contrast to our results, Pavlakis et al. (2010) found only one overlooked 
cancer and one ASAP among 250 patients whose needle biopsies were routinely 
immunostained with p63, CK34betaE12, and AMACR. Moreover, Paner et al. 
(2008) concluded in a review article that no routine immunostainings are required. 
Due to the short follow-up time, no prognostic comparisons between routine 2IHC 
and current practices can be made.  
Clearly, patients with aggressive disease but with minimal findings in needle 
biopsies need to be identified to receive adequate treatment. In some cases, routine 
2IHC may yield detection of clinically insignificant cancers, and there is a risk of 
overtreatment. For the pathologists, however, improved sensitivity indicates better 
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diagnostic quality. In addition, we ensure the equality of patients by performing 
2IHC non-selectively on samples from all patients.  
In laboratory medicine, improved sensitivity is frequently achieved at the 
expense of decreased specificity. In the present study, 14 putative cancers were 
found in new patients. Of these, the consensus of five pathologists (defined as 
agreement of 4/5) yielded 8 cancer diagnoses, one ASAP, and five cases in which 
no consensus was found. The eight cancers diagnosed by consensus will be treated 
as carcinoma according to their prognostic parameters. The only consensus case of 
ASAP will likely be submitted to repeated biopsies in addition to frequent PSA 
monitoring. The five cases in which no consensus was reached may represent false 
positives. The study by Pavlakis et al. (2010) found a substantial number of benign 
glands negative for the basal cell markers p63 and CK34betaE12, potentially 
representing false positives. In our study, however, three of the five cases without 
consensus were submitted to re-biopsies, and all were identified as GS 3+3=6 
cancer. Because of this result, we believe that routine 2IHC is valuable in 
pinpointing small neoplastic lesions. 
Given our results that routine 2IHC increases the detection of small cancer foci, 
multifocal cancers should also be more easily detected, affecting prognostic 
parameters from needle biopsies e.g. number of positive cores. Some patients with 
focal cancer observed on H&E staining would be given a cancer diagnosis based on 
multiple cores if 2IHC was performed and would receive active treatment instead of 
surveillance. According to the current national guidelines in Finland (Suomalainen 
Lääkäriseura Duodecim ja Suomen Urologiyhdistys ry. at 
http://www.kaypahoito.fi/web/kh/suositukset/naytaartikkeli/tunnus/hoi11060#s8 
25.02.2011), the number of actively treated patients would likely increase if more 
cancer-positive cores were found. These consequences need to be monitored in a 
longer follow-up study.  
The number of cases with ASAP as the worst diagnosis was also increased 
following our protocol, the majority of which would have been diagnosed as benign 
without immunohistochemistry. It is difficult to estimate the significance of this 
finding, but due to clinicians’ awareness of these cases, some cancers may be 
detected earlier. 
In general, dual-color immunostainings were considered technically successful 
and easy to interpret. In approximately 15% of obvious cancer cases that were 
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negative for basal cell markers, immunostaining against AMACR was weak and/or 
patchy. This result may reflect the biology of prostate cancer, but technical failure 
cannot be excluded. In previous reports, the frequency of compromised staining of 
AMACR has been similar, between 0% and 18% (Jiang et al. 2001, Zhou et al. 
2004, Browne et al. 2004, Jiang et al. 2005).  
Routine 2IHC staining of all prostate biopsies was associated with diminished 
microscopy time. One explanation for this efficiency can be deduced from the study 
protocol, in which the 2IHC was first briefly screened. After screening the 2IHC 
slide, the risk of missing a minute cancer is lower. The interpretation of 2IHC-
stained slides could be performed so rapidly because the blue stain is readily 
distinguished from the background when scanning the slides with a 4 x objective. 
As expected, this stain served as an alarm. Additionally, 2IHC was helpful in 
differential diagnostics, making decision-making more efficient.  
The costs of the 2IHC protocol must be weighed against the benefit of finding 
more cancers. If we compare only the reagent costs of routine 2IHC (50 € per cancer 
or 600 € per detected additional cancer), for instance, to the costs of oncological or 
surgical treatments, the costs do not seem to be extremely high provided that the 
cancer incidence in the needle biopsies remains high. The total exact costs of routine 
2IHC are difficult to estimate because this protocol would likely: 
 increase the number of cancer diagnoses 
 increase the number of ASAP diagnoses, leading to repeated biopsies 
 resolve most ASAP diagnoses from H&E to benign or malignant 
 resolve approximately half of the HGPIN diagnoses based on H&E 
staining to either benign or malignant 
 influence prognostic parameters and thereby affect the chosen treatment  
 decrease the microscopy workload of the pathologist   
 increase dictation time 
We consider that the costs of routine 2IHC may be tolerable, at least in the case of 
six biopsies from one “lobe” of the prostate embedded in the same paraffin block. 
However, individually embedded needle biopsies would yield six-fold higher costs, 
which may be too high for routine diagnostics. In conclusion, considering that the 
quality of treatment is as good as the quality of diagnostics, the routine use of 2IHC 
could be tested in clinical use, at least for pooled (6+6) biopsies. 
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3. Prognostic factors in needle 
biopsies (III, IV) 
Pre- and post-treatment nomograms are used to predict patient outcome. Indeed, 
many nomograms have been created for all recommended treatment forms 
(D'Amico 1999, Kattan et al. 1999, Kattan et al. 2001, Smaletz et al. 2002, Makarov 
et al. 2007, Zelefsky et al. 2007, Spiess et al. 2010). There are also numerous 
prognostic studies of histopathological parameters of needle biopsies from 
surgically treated patients (Nelson et al. 2002, Winkler et al. 2004, San Francisco et 
al. 2004, Villamon-Fort et al. 2007, Brimo et al. 2008, Rajab et al. 2010). 
Integration of the sum of the complex data available from individual studies has 
yielded simple online nomograms meant to aid clinicians in decision-making. These 
include, for example, nomograms for different treatments of prostate cancer at the 
Memorial Sloan-Kettering Cancer Center (MSKCC at 
http://www.mskcc.org/applications/nomograms/prostate/index.aspx 1.3.2011) and a 
recently published risk calculator by Katz et al. (2010) 
(http://www.capcalculator.org 1.3.2011). 
Several parameters reported from core biopsies are considered to be predictive 
rather than prognostic factors and correlate to findings from the radical 
prostatectomy specimen. Prognostic factors may differ in other treatment forms, 
including ADT, in which clinicians need to rely on the biopsy material only. A 
nomogram for ADT-treated, non-CRPC patients was recently created, but 
complementary histopathological parameters were not included (Cooperberg et al. 
2009). Although ADT is used most frequently in advanced disease, it has been used 
for elderly men who are not suitable for intent-to-cure therapies but desire to be 
actively treated instead of following a course of watchful waiting. Because no 
radical therapy had been applied in our patient cohort, this patient sample allowed 
for a unique prognostic study. 
The strongest prognostic factors in the endocrine-treated cohort studied with 
prostate needle biopsies were GS, pre-treatment PSA value, multiple PNI, and cT 
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stage. Anatomically, nerve bundles are located near the capsule of the prostate, and 
perineural growth indicates the minimum subcapsular infiltration of cancer. 
Moreover, the most common mode of local spreading of prostate cancer through the 
capsule occurs inside the perineural space (Villers et al. 1989). Because PNI was 
identified as an independent prognosticator and not only a surrogate marker for cT 
stage, perineurally growing cancer may receive a growth advantage from neural 
paracrine factors. This growth advantage may then interfere with apoptotic control 
(Yang 1996). Recently, Chiu et al. (2010) described a survival mechanism for 
prostate cancer cells in endocrine-treated patients. Androgen deprivation therapy 
induces the expression of NAIP, which belongs to a larger family of IAP proteins. 
Neural expression of NAIP may lead to apoptotic escape from of cancer cells in 
vivo and possibly explains the increased risk for biochemical recurrence in 
hormone-treated patients with PNI. Unfortunately, no literature regarding NAIP 
expression in peripheral nerves could be found.  
Two trends regarding the detection and diagnosis of prostate cancer have 
occurred over the last two decades: i) cancers are detected earlier, when they are 
smaller and better differentiated, but ii) they are graded as more aggressive than in 
the past due to grade inflation (Albertsen et al. 2005a). Despite recent modifications 
of GS scoring and the Will Rogers phenomenon (Thompson et al. 2005), the GS 
remains the most powerful prognosticator in prostate cancer (Epstein et al. 2005, 
Helpap and Egevad 2006). As a result of the modification of the Gleason grading 
system, the cut-off between low-grade and high-grade cancer may have shifted 
upwards (Helpap and Egevad 2009, Stark et al. 2009). A similar phenomenon was 
observed also in our study, in which non-conventional grouping of Gleason scores 
(GS 3+4 vs. 4+3) gave the best prognostic values. Similar improvements were 
additionally noted in both the WGS and OGS methods of assessing Gleason scores. 
In a multivariate analysis, OGS was the only independent prognostic factor of the 
six different grading systems (both conventional and reclassified versions of WGS, 
OGS and CGS). However, in univariate analysis, WGS performed slightly better 
than OGS, with a relative risk of 2.8 (2.5-3.1) compared to 2.6 (2.4-2.9) for OGS. 
Relative risks from a three-category variable may be difficult to determine, but we 
conclude that both scoring systems offer similar information regarding patient 
prognosis. Lotan and Epstein (2010) examined needle biopsy studies and reported 
that the prognostic cut-off between low-grade and high-grade cancer shifted from 
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Gleason 6 vs. 7 to Gleason 3+4 vs. 4+3 due to the revised ISUP guidelines. This 
conclusion was also suggested by prostatectomy specimens studied by Helpap and 
Egevad (2008). We confirm this phenomenon for needle biopsy material, at least in 
our unique, endocrine-treated cohort. If we consider the impact of the modified GS, 
some cases will have a GS 3+4=7 instead of a GS 3+3=6. Logically speaking, cases 
with a GS 4+3=7 remain unchanged, making this category more resistant to grade 
inflation, emphasizing its prognostic value. 
Cell proliferation markers have the best prognostic value among biomarkers for 
prostate cancer but are still not superior to the Gleason sum. Due to the established 
problems of Gleason grading, including low reproducibility and high interobserver 
variability, biomarkers could potentially have additive value in Gleason score 
subgroups. Several earlier studies have shown that the fraction of proliferative cells 
is useful in risk assessment (Visakorpi et al.1991, Bubendorf et al. 1998, Pollack et 
al. 2004, Laitinen et al. 2008, Zellweger et al. 2009). In the present study, a Ki-67 
immunostaining index over 10% was capable of detecting patients with a high risk 
for progression. The modified GS was very strong prognosticator on the both ends 
of the scale, but GS 7 was assessed in 32% patients, indicating moderate risk. These 
patients could be further substratified by GS 3+4 vs. 4+3 to low- vs. high-risk 
groups, respectively. An important and clinically relevant observation was that Ki-
67 was especially useful in identifying patients with aggressive disease within the 
moderate risk group with GS 7. In conclusion, IHC for Ki-67 is routinely available 
in virtually all pathology laboratories, and its use, for example with a cut-off value 
of 10 %, could be encouraged for intermediate risk patients (GS 7).  
Our previous results with MCM7 and EZH2 suggested that these biomarkers 
were independent prognostic factors in surgically treated patients, especially when 
their expression indexes were combined (Laitinen et al. 2008). In the present study 
of endocrine-treated patients, both biomarkers were significant predictors in the 
univariate analysis. However, we were unable to repeat our earlier findings in the 
multivariate analysis. All studied variables, including morphological biopsy 
parameters, were associated with each other. Moreover, the prognostic abilities of 
these variables in the univariate analysis were rather similar (TABLE III). When 
many good prognosticators are identified, small differences and coincidence may 
play a role in their perceived importance. In addition, there are several other 
differences that could explain discordant findings between the two studies, including 
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materials (core biopsy vs. radical prostatectomy) and methods (manual vs. 
automated counting). Furthermore, the modified recommendations with respect to 
Gleason grading may have led to a better prognostic value of the GS.  
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4. Towards better diagnostics in the 
PSA era (II, IV) 
The processing of prostate biopsies is variable and debated. A recent multicenter 
questionnaire by ENUP showed that slightly more than half of European centers 
utilize individual embedding of needle biopsies, while other centers embed 2-6 
biopsies in the same paraffin block (Lars Egevad 2011, personal communication). 
The embedding procedure influences Gleason scores with respect to whether the 
worst or overall GS is given and, therefore, the choice of treatment. Individual worst 
Gleason scores were recommended by the ISUP 2005 Consensus Conference if the 
biopsies are immersed in separate formalin containers and embedded individually 
(Epstein et al. 2005). The use of individual embedding may yield less fragmented 
needle biopsy tissue cores but is more laborious.  
Another disadvantage of pooled biopsies is the loss of site information. 
Information regarding the location of the focus would be essential when considering 
local therapy (e.g., targeted brachytherapy or cryotherapy) in focal carcinomas 
(Eggener et al.2007, Karavitakis et al. 2010). Moreover, the anatomic localization of 
carcinoma foci is useful when planning nerve-sparing radical prostatectomy and for 
avoiding side effects of external-beam radiotherapy. Although there is a significant 
degree of variation between laboratories, only four studies comparing predictive or 
prognostic abilities of worst and overall Gleason score have been published (Forman 
et al. 2000, Kunz and Epstein 2003, Poulos et al. 2005, Kunju et al. 2009). Of these, 
only the study by Kunju et al. (2009) was performed using the modified Gleason 
system. 
Embedding of multiple biopsies in the same paraffin-block is not recommended 
by the ISUP because of assumed fragmentation and technical difficulties in 
flattening the biopsies (Epstein et al. 2004, Epstein et al. 2005). However, these 
presumptions have not been thoroughly studied. The median length of the biopsies 
in the European Randomized Study of Screening for Prostate Cancer was 56.3 mm, 
and the length of glandular tissue was 44.6 mm (Wolters et al. 2008). Based on our 
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experience of consultation biopsies from other institutes, there are no major 
differences in the length or quality of individual, double-embedded or pooled needle 
biopsies. 
 
Future directions 
 
Optimal methods for embedding pooled biopsies are needed to facilitate the 
important application of routine 2IHC, the costs of which would otherwise be 
prohibitive. We are currently testing two recent innovations, engraved paraffin 
blocks (Tolonen et al., manuscript under preparation) and the Paraform® 
Sectionable Cassette System from Sakura (Dimenstein IB 2010) to: 
 maintain locus information of the biopsies,  
 flatten them properly 
 enable 2IHC stainings from one (6 biopsies) or both sides (12 biopsies) 
simultaneously 
The quality of individually embedded biopsies vs. pooled biopsies will be compared 
by measuring their areas with the aid of digital image analysis. The development of 
universally acceptable technical solutions for pooled biopsy protocols will gradually 
facilitate the routine use of 2IHC. In turn, this advance will hopefully improve the 
diagnostic quality of random needle biopsies of the prostate gland in the post-PSA 
era.  
Due to intra- and interobserver variability problems associated with Gleason 
grading, our group is also developing an automated analysis system of 2IHC-stained 
prostate biopsies. The color components of the digitalized image of the 2IHC 
staining (blue and brown) are relatively easy to separate by color deconvolution and 
thresholding (Ruifrok and Johnston 2001). Previously, texture analysis of prostate 
biopsies has been challenging, but it may be possible through digitalized 2IHC 
images following initial editing of images by deconvolution and thresholding. 
Current applications of texture analysis, such as local binary pattern (LBP) (Ojala et 
al. 1994), are able to recognize patterns that were previously considered difficult. 
For example, face-recognition using LBP is already incorporated in common photo 
library software and cameras. Texture analysis of digitalized 2IHC images will 
hopefully yield a more reproducible method for assessing Gleason patterns in the 
near future.  
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Until computer-based analysis of prostate biopsies is a reality, pathologists will 
need to perform the scoring. Consistent scoring between pathologists is achieved 
with the aid of reference figures. Both the old and new “official” figures of the 
Gleason patterns (Figure 5, pp. 31 and Figure 6, pp. 33) need to be updated. Both 
suffer from major errors due to modified recommendations (Epstein 2010). To 
resolve this problem, our preliminary testing with digital images of 2IHC slides 
resulted in a new diagram (Figure 13). All cancer patterns were cut from digitalized 
images of 2IHC slides and thus represent real (i.e., non-stylized) adenocarcinomas. 
To generate the black and white schema, the cancer pattern images were converted 
to binary mode, thresholded and median-filtered in ImageJ. Some details have been 
manually painted. We have also attempted to eliminate the overlapping of patterns 
observed on several grades in earlier versions by Gleason (Figure 5, pp. 31) and 
Brunbaugh (Figure 6, pp. 33). The key changes are: 
 Grade 1 does not exist. 
 Grade 2 consists of tightly packed round glands with some variation in 
size and shape. No infiltrative patterns are accepted. 
 All infiltrative cancer, that forms separate glands are included in grade 3. 
 Small glands with lumens are also included in grade 3. 
 Small glands without lumens are included grade 4. 
 All cribriform patterns are included in grade 4 (except if with 
comedonecrosis, which is grade 5) 
 
With some minor refinements, Figure 13 is our proposal for a new reference figure 
of Gleason patterns and should be consistent with the current recommendations of 
grading prostatic adenocarcinoma.  
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Figure 13. Updated Gleason patterns. Left: true prostate cancer patterns according to 
Gleason grades. Patterns were cut from digital images of 2IHC slides. Right: our proposal 
for a new reference picture of modified Gleason scores. 
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CONCLUSIONS 
The key findings of the study contribute to the existing literature regarding 
prostate cancer development, diagnostics of small cancers, and prognostic factors in 
the PSA era. 
The main conclusions of this study are as follows. 
 
1. BAX and BCL-2 are overexpressed in some foci in morphologically 
normal areas of cancerous prostates, consistent with the field effect 
theory.  
2. Routine 2IHC of interval sections of prostate needle biopsies improves 
diagnostic sensitivity of prostate cancer with less time spent on 
microscopy. 
3. Gleason score, PSA value, multiple PNI and cT-stage are independent 
prognostic factors in endocrine-treated prostate cancer patients. Gleason 
score 3+4 versus 4+3 is a prognostic watershed between low-grade and 
high-grade cancer. 
4. All biomarkers analyzed (EZH2, Ki-67 and MCM7) are significant 
individual prognosticators, and have comparable relative risks to those of 
histopathological variables. Ki-67 is especially useful in assessing the risk 
of a subgroup of patients with Gleason scores of 7. 
5. Worst and overall Gleason scores provide comparable information in the 
modified Gleason score era. The use of pooled biopsies is a cost-efficient 
way to perform routine 2IHC, and its use should be weighed against the 
missed locus information. 
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multivariate Cox regression analysis, with 
biochemical recurrence as an endpoint.
 
RESULTS
 
• Biomarkers EZH2 (relative risk [RR] 2.0, 
95% confidence interval 1.2–3.3), Ki-67 (3.4, 
2.1–5.5) and MCM7 (2.4, 1.5–3.9) were 
significantly associated with progression-
free survival in a univariate analysis.
• Ki-67 immunostaining index detected 
high-risk patients with GS of 7 (9.1, 
8.0–10.3).
• In a multivariate analysis with non-
conventional GS groups 5–7 (3 
 
+
 
 4), 7(4 
 
+
 
 
3)–8, and 9–10, the independent prognostic 
markers were pretreatment GS (2.2, 1.5–3.2), 
prostate-specific antigen (PSA) level (2.1, 
1.1–4.2), perineural invasion (PNI) (1.6, 
1.2–2.2), and clinical T-stage (cT) (1.9, 
1.0–3.7).
• Combination of the independent markers 
(PSA level 
 
>
 
20 ng/mL or GS 
 
>
 
3 
 
+
 
 4 or PNI 
 
>
 
3 
or cT 
 
>
 
2) yielded best risk stratification (RR 
11.6, 10.4–12.7).
 
CONCLUSIONS
 
• GS remains one of the most important 
prognostic factors in prostate cancer. 
However, the refined guidelines by ISUP 
2005 might have shifted the threshold 
between low-grade and high-grade cancers 
from GS 6 vs 7 to GS 3 
 
+
 
 4 vs 4 
 
+
 
 3.
• PNI is an independent prognostic marker 
superior to cT.
• Ki-67 is the most useful biomarker in 
detecting patients with GS 
 
=
 
 7 at high risk 
for progression.
 
KEYWORDS
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Gleason score, perineural invasion, Ki-67, 
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What’s known on the subject? and What does the study add?
 
Gleason score is a strong prognostic factor, but its reproducibility is not optimal. Our data 
show that multipte perineural invasion and Ki-67 index are signs of early biochemical 
progression in patients treated with hormonal therapy.
Study Type – Prognosis (case series)
Level of Evidence 4
 
OBJECTIVE
 
• To evaluate the prognostic value of 
histopathological variables and 
immunostainings of biomarkers enhancer of 
zeste homologue 2 (EZH2), Ki-67 and 
minichromosome maintenance protein 7 
(MCM7) from core biopsies of hormonally 
treated patients with prostate cancer.
 
PATIENTS AND METHODS
 
• Biopsies of 247 primarily endocrine-
treated patients were analysed for 
histopathological characteristics and 
Gleason scores (GS) according to the revised 
guidelines of International Society of 
Urologic Pathology (ISUP) consensus 
conference 2005.
• Immunohistochemical stainings were 
analysed with the aid of digital image 
analysis.
• The prognostic value of the 
histopathological variables and the 
biomarkers was analysed with univariate and 
 
INTRODUCTION
 
Prostatic adenocarcinoma is the most 
frequent non-cutaneous malignancy in the 
Western world and causes substantial 
mortality and morbidity [1]. Treatment 
options in localized disease include radical 
nerve-sparing prostatectomy, radiation 
therapy and active surveillance [2]. Androgen 
deprivation therapy (ADT) is recommended for 
extraprostatic or metastatic disease [2]. 
Primary ADT has also been used in localized 
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disease, despite a lack of conclusive evidence 
for its benefit [3]. Almost all patients initially 
respond to androgen deprivation. However, 
disease progression eventually occurs due to 
the emergence of castration-resistant 
prostate cancer (CRPC) [4]. For such CRPC, 
there are no curative therapies available, 
although recent trials have indicated that 
docetaxel prolongs the life of patients with 
CRPC for a few months [5].
Several nomograms have been created to 
predict the outcome. The strongest prognostic 
factors are clinical TNM stage, pretreatment 
PSA level, and Gleason score (GS) [6,7]. Other 
suggested prognostic factors are patient age, 
the total percentage of cancer (TPC), the 
greatest percentage of a biopsy core involved 
by cancer (GPC), the percentage of cancer-
positive cores (CPC) and perineural invasion 
(PNI) [8–13]. The prognostic value of 
these variables has not been evaluated 
systematically from biopsy specimens of 
primarily ADT-treated patients. Several 
immunohistochemical and genetic markers of 
outcome have also been proposed. However, 
none of them has become routinely used in 
clinical practice. Most of the biomarkers are 
associated with cell proliferation activity and 
cell cycle control. One of the most promising 
and extensively studied prognostic 
proliferation markers is Ki-67 (MIB-1) 
[14–18]. Other potential cell proliferation 
biomarkers include enhancer of zeste 
homologue 2 (EZH2), which is an evolutionary 
highly conserved epigenetic regulator that 
functions as a histone methyltransferase [19]. 
Overexpression of EZH2 is associated with 
poor prognosis in several cancers, including 
prostate carcinoma [20–24]. Our previous 
study indicated that overexpression of EZH2 is 
an independent prognostic factor in surgically 
treated patients [25]. Another suggested 
prognostic marker is minichromosome 
maintenance protein 7 (MCM7), which is a 
critical component of the DNA replication 
licensing complex [26,27]. In our earlier study 
of prostatectomy-treated patients, MCM7 
was a strong prognostic marker, especially in 
combination with EZH2 [25].
Most of the recent prognostic studies 
have focused on patients treated with 
prostatectomy. However, many patients are, 
even today, primarily treated with hormonal 
therapy. The utility of docetaxel in treating 
prostate cancer has raised questions about 
how to identify patients who will progress 
early during endocrine treatment. The aim of 
the present study was to evaluate the 
prognostic significance of the suggested 
tissue markers in endocrine-treated patients 
with prostate cancer.
 
MATERIAL AND METHODS
 
The present study has been approved by the 
Ethical Committee of Tampere University 
Hospital and the National Authority for 
Medicolegal Affairs. From 1999 to 2003, 295 
consecutive new patients with prostate 
cancer diagnosed from core biopsies were 
primarily hormonally treated at Tampere 
University Hospital. This is approximately 25% 
of all the prostate cancers treated at the 
hospital. The indication for endocrine 
treatment was advanced disease or patients 
being unwilling or unsuitable for therapy of 
curative intent due to their general condition 
but wanting to have active treatment instead 
of watchful waiting. None of the patients 
received other forms of cancer treatment, 
such as radiation or surgery, before 
progression. Representative formalin-fixed 
and paraffin-embedded first cancer diagnosis 
biopsy samples were available from 247 
(83.7%) patients. Complete clinical follow-up 
data were available from 292 patients. 
Biochemical progression was defined as a 
 
≥
 
25% rise in PSA level with a PSA value 
 
≥
 
2.0 ng/mL above nadir in two consecutive 
measurements according to The Prostate 
Cancer Clinical Trials Working Group 
guidelines [28]. To assess the M-stage of the 
patients, bone scintigraphy was done in all 
symptomatic patients and in asymptomatic 
patients when PSA level was 
 
≥
 
20 ng/mL or 
when the prostate cancer was histologically 
aggressive (original GS 
 
=
 
 8–10). In the 
analyses, MX patients were considered as M0 
due to the fact that they represented cases 
with low PSA levels and low GS and because 
their prognosis was as good as the prognosis 
for M0 patients. The distribution of primary 
hormonal treatments was surgical castration 
(
 
n
 
 
 
=
 
 55), luteinizing-hormone releasing-
hormone analogue (
 
n
 
 
 
=
 
 208), antiandrogen 
bicalutamide (
 
n
 
 
 
=
 
 27) and maximal androgen 
blockade (
 
n
 
 
 
=
 
 3).
One slide from each prostate lobe was 
available. The mean (range) number of core 
biopsies from one lobe was 4.5 (1–7). The 
most representative haematoxylin and eosin 
(H&E)-stained slide, consisting of biopsies 
from the left or right lobe, was selected and 
scanned with Aperio ScanScope® XT (software 
version 9; Aperio Technologies, Vista, CA, USA) 
and viewed in JPEG2000 format using 
JVSview software (version 1.2) [29]. The re-
evaluated variables were GS, GPC, CPC, 
number of nerves with PNI, and the diameter 
of the greatest perineurally invaded nerve. The 
GS were re-evaluated according to the new 
recommendations by International Society of 
Urologic Pathology (ISUP) [30]. The combined 
GS for the re-evaluated biopsies of one lobe 
was used in the analyses. For GPC, the 
percentage of cancer in each core was 
estimated as the proportionate length of 
cancer to the total length of the biopsy. The 
length of benign tissue between separate 
expansive cancer foci was subtracted. The 
length of infiltrating carcinoma glands 
intervening normal glands was counted as 
carcinoma. TPC (including both lobes) and 
WHO grades were obtained from the original 
pathology reports. PNI was defined as 
infiltration of carcinoma into the perineural 
space. An entire encircling was not required. 
The diameter of greatest nerve with PNI was 
measured from virtual slide screenshots using 
the public domain image analysis software 
ImageJ (version 1.36b) (http://rsbweb.nih.gov/
ij/index.html) [31]. The evaluations were done 
by one of the authors (TTT) in a blinded 
fashion, i.e. with no awareness of the clinical 
outcome.
Immunostainings were performed with 
antibodies against Ki-67 (MM1, Novocastra
 
TM
 
 
Laboratories Ltd., Newcastle Upon Tyne, UK), 
EZH2 (NCL-L-EZH2, clone 6A1, Novocastra
 
TM
 
 
Laboratories Ltd), and MCM7 (sc-9966, Santa 
Cruz Biotechnology, Inc. Santa Cruz, CA, USA) 
with Power Vision1
 
TM
 
 Poly-HRP Histostaining 
Kit (ImmunoVision Technologies Co, Daly City, 
CA, USA) according to the manufacturers’ 
instructions. The stainings were carried out in 
Autostainer 480 (Lab Vision Corp, Fremont, 
CA, USA). Briefly, slides were autoclaved in 
pretreatment buffer (5 mM Tris-HCl/L mM 
EDTA, pH 9) at 121 
 
°
 
C for 2 min, followed by 
incubation with the primary antibody diluted 
in pre-block solution (Ki-67 1:1500, EZH2 
1:300, MCM7 1:500) overnight. After washing 
and blocking, the bound primary antibody 
was visualized with the PowerVision
 
TM
 
 Poly-
HRP IHC Detection Kit (ImmunoVision 
Technologies Corporation, Brisbane, CA, USA). 
The slides were counterstained with 
haematoxylin. The digitalization of the 
immunostained slides was performed using 
the virtual slide scanner set-up as described 
earlier. Screenshots of the three hotspot areas 
showing the highest immunostaining were 
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captured from each slide. The images were 
analysed with ImmunoRatio, which is a tool 
for analysing nuclear immunostainings in 
haematoxylin-counterstained tissue sections 
[32]. Analysis was based on the colour 
deconvolution for the separation of the 
staining components [diaminobenzoate (DAB) 
brown and haematoxylin blue] and adaptive 
thresholding for defining staining positivity 
[33]. The proportion of brown-stained area 
over brown 
 
+
 
 blue was defined as the labelling 
index. The results of the automated analysis 
were verified by one of the authors (TTT) 
comparing the original image to the 
segmented image (Fig. 1).
For statistical analysis, Fisher’s exact, chi-
square and one-way 
 
ANOVA
 
 tests were used to 
evaluate the associations between the 
variables. Survival analysis was performed 
using the Kaplan–Meier method and the 
statistical significance of survival differences 
between patient groups was determined with 
the Mantel–Cox test. The univariate and 
multivariate Cox regression analyses were 
performed to calculate the relative risk (RR) 
estimates and to evaluate the independence 
of the prognostic markers.
 
RESULTS
 
The median (range) age of the patients at the 
time of diagnosis was 73.6 (52.7–88.8) years. 
The median (range) follow-up time was 56.5 
(8–104) months. The months pretreatment 
PSA level was 16.5 (1.9–10 750) ng/mL. Over 
half (54.9%, 162/295) of the patients had 
localized disease (cT1–T2). One-third of 
the patients (33.6%) experienced PSA 
progression. Cancer-specific mortality was 
6.4% (19/295) and deaths due to other 
reasons occurred in 25.7% (76/295). Re-
evaluated GS and other histopathological 
variables were successful in 247 cases. GS 
distribution was as follows: GS 
 
<
 
 7, 
 
n
 
 
 
=
 
 60 
(24.3%); GS 
 
=
 
 7, 
 
n
 
 
 
=
 
 79 (32.0%); and GS 
 
>
 
 7, 
 
n
 
 
 
=
 
 108 (43.7%). There were no cases with 
GS 
 
=
 
 2–4. The distribution of the basic 
characteristics is presented in Table 1.
Because the tissue in the paraffin blocks runs 
out after repeated sectioning, the number of 
successful cases varied in different stainings. 
Immunohistochemical analysis was 
successful in 216 cases for Ki-67, 209 cases 
for EZH2, and 211 cases for MCM7. For the 
data analysis, mean values from the three 
hotspots were used. Two example cases 
including H&E stainings and 
immunostainings of the needle biopsies can 
be viewed at http://jvsmicroscope.uta.fi/
tolpub2010/.
The Kaplan–Meier curves of the progression-
free survival are shown in Figs 2–4. In the 
subgroup of GS 7, the rate of progression was 
lower in Gleason grades 3 
 
+
 
 4 than in 4 
 
+
 
 3. 
The best prognostic value was achieved by 
reclassifying GS grouping as 5–7 (3 
 
+
 
 4), 
7 (4 
 
+
 
 3)–8, and 9–10 (
 
P
 
 
 
<
 
 0.001, log-rank 
test) (Fig. 2A). Also, the traditional GS groups 
 
<
 
 7, 7 and 
 
>
 
7, were strongly associated with 
progression-free survival (
 
P
 
 
 
<
 
 0.001) (Fig. 2B). 
Both the advanced against localized (T3–4 
against T1-2) cT-stage (
 
P
 
 
 
<
 
 0.001) and M-
stage (M1 against M0) (
 
P
 
 
 
<
 
 0.001) were 
significantly associated with progression-
free time (Fig. 2C,D). In the analysis of 
pretreatment PSA level, we used a 
dichotomized grouping of PSA 
 
≤
 
 20, 
 
>
 
20 ng/
mL as reported by Graff 
 
et al
 
. [34]. PSA level 
 
FIG. 1. 
 
An example of a typical automated analysis of two Ki-67 immunostainings. Top panels: hotspot areas 
were selected and captured for analysis of the immunostainings (DAB brown and haematoxylin blue); 
bottom panels: the result of automated analysis of the same hotspots (below). Magnification, 
 
∼
 
100
 
×
 
.
 
TABLE 1 
 
Distribution of the clinicopathological 
variables
n
 
 (%)
Clinical T-stage (
 
n
 
 
 
=
 
 295)
cT1–2 161 (55)
cT3–4 134 (45)
M-stage (
 
n
 
 
 
=
 
 295)
Mx* 127 (43)
M0 111 (38)
M1 57 (19)
Gleason score (
 
n
 
 
 
=
 
 247)
2–4 0 (0)
5 4 (2)
6 56 (23)
7† 79 (32)
8 42 (17)
9 53 (21)
10 13 (5)
PSA level, ng/mL (
 
n
 
 
 
=
 
 295)
 
≤
 
20 168 (57)
 
>
 
20 127 (43)
Age, years (
 
n
 
 
 
=
 
 295)
 
<
 
60 13 (4)
60–70 70 (24)
70–80 174 (59)
80
 
+
 
38 (13)
 
*Mx were considered M0 in statistical 
calculations. †
 
n
 
 
 
=
 
 50 for GS 3 
 
+
 
 4 and 
 
n
 
 
 
=
 
 29 for 
GS 4 
 
+
 
 3.
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was found to be highly significantly 
associated with progression-free survival (
 
P
 
 
 
<
 
 
0.001) (Fig. 2E). The other histopathological 
features, CPC (
 
P
 
 
 
<
 
 0.001, Fig. 2F), GPC (
 
P
 
 
 
<
 
 
0.001, Fig. 2G), TPC (
 
P
 
 
 
<
 
 0.001, Fig. 2H) and the 
number of PNI (
 
P
 
 
 
<
 
 0.001, Fig. 3A), were also 
associated with progression-free survival. 
WHO grade, which was derived from the 
original pathology reports, showed a 
significant association with progression (
 
P
 
 
 
<
 
 
0.001, Fig. 3B). The only histopathological 
variable not associated with progression was 
the diameter of the greatest nerve with PNI 
(
 
P
 
 
 
=
 
 0.75).
Ki-67 staining index over 10% identified a 
quintile with a very high risk of progression 
(
 
P
 
 
 
<
 
 0.001, Fig. 3C). For the MCM7 (
 
P
 
 
 
=
 
 0.001) 
and EZH2 (
 
P
 
 
 
=
 
 0.0041) immunostainings, the 
best dichotomous threshold values were 
determined with Kaplan–Meier curves 
utilizing Mantel–Cox tests, both of which 
gave values close to the medians (Fig. 3D,E, 
respectively).
Inside the sub-group of patients with GS 
 
=
 
 7, 
the progression-free time for patients with 
Gleason grading 4 
 
+
 
 3 was significantly 
shorter than for patients with grading 3 + 4 
(P = 0.013, Fig. 4A). In the same patient group, 
Ki-67 expression with a threshold value of 
10% was highly capable of finding patients 
with early PSA recurrence (P < 0.001, Fig. 4B).
The RR and 95% CIs were first calculated with 
univariate analysis utilizing a Cox regression 
model and are presented in Table 2. All of the 
markers were statistically significant as 
individual prognostic factors. To evaluate 
association of the variables against each 
other, we utilized a chi-squares test of the 
categorized markers. All variables were 
significantly (P < 0.05) associated with each 
other. Thus, to evaluate the independent 
prognostic power of the histopathological 
variables and the biomarkers, we utilized a 
multivariate Cox regression model. The first 
multivariate analysis was performed with the 
conventional GS grouping of <7, 7 and >7. 
Pretreatment PSA level, GS, number of PNI 
and cT-stage were found to be independent 
predictors of progression (Table 2). None of 
the proliferation biomarkers showed 
independent prognostic power. Because GS 
groups 3 + 4 and 4 + 3 showed a clearly 
distinct prognosis (Fig. 2F), we performed a 
second multivariate analysis with reclassified 
GS groupings as 5–7 (3 + 4), 7 (4 + 3)–8, 9–10. 
In the analysis, the modified GS grouping was 
the strongest independent prognostic factor. 
Other independent prognosticators were 
pretreatment PSA level, number of PNI and 
cT-stage (Table 2).
Finally, we combined the four independent 
markers from the multivariate analysis into a 
single risk estimate of progression. The 
threshold values were PSA level >20 ng/mL, 
cT-stage >2, and PNI >3. In addition, three 
cut-offs for Gleason scores were tested 
(Fig. 4C–E). The best risk stratification (RR = 
11.6, 95% confidence interral 10.4–12.7) was 
achieved when Gleason score threshold 3 + 4 
FIG. 2. Kaplan–Meier progression-free survival curves according to reclassified GS (A), GS (B), cT-stage (C), M-
stage (D), pretreatment PSA-value (E), percentage of cancer-positive cores (CPC) (F), greatest percentage 
cancer in a single biopsy (GPC) (G), and total percentage cancer (TPC) (H). P values according to Mantel-Cox 
test are shown.
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was utilized (Fig. 4C). Risk for progression was 
very low (four of 61, 6.6%) in patients in the 
low-risk arm.
DISCUSSION
Primary ADT is offered to patients with 
advanced disease or those who are otherwise 
not suitable for intent-to-cure therapy, e.g. 
elderly patients with localized disease [2,3]. In 
patients with locally advanced tumours and 
patients with poorly differentiated localized 
cancers, the use of ADT is associated with 
improved cancer-specific survival [3]. 
However, a majority of the patients with a 
well- to moderately differentiated localized 
disease are not likely to benefit from ADT [3]. 
Graff et al. [34] have shown that in patients 
with localized cancer receiving primary ADT, 
GS ≥7, PSA level ≥20 ng/mL and a low 
comorbidity index are independent predictors 
of shorter cancer-specific survival. After 
progression to CRPC, the significance of GS 
and PSA level diminishes, and the most 
important prognostic factors are general 
markers, such as haemoglobin, lactate 
dehydrogenase and albumin [35]. Since 
docetaxel has now been shown to prolong the 
lives of patients with CRPC [5], the question of 
timing of the treatments has arisen. There is a 
need for indicators for the early use of 
docetaxel [5]. Until recently, there have not 
been, for example, nomograms for endocrine-
treated non-CRPC patients. In addition, most 
studies with detailed histopathological 
interpretations of biopsy cores have 
concentrated on radical treatments. Recently, 
a risk assessment tool for patients receiving 
primary ADT was developed in a large 
multicentre study [36]. Like other nomograms, 
the tool Japan Cancer of the Prostate Risk 
Assessment (J-CAPRA) is based on PSA level, 
GS and cTNM-stage and validated in both 
localized and advanced disease. The major 
limitation of the model is that it lacks 
complementary histopathological 
information from biopsy cores.
In the present study, almost all 
histopathological variables (except diameter 
of the greatest nerve invaded) were strong 
indicators of progression-free survival. The 
modified GS was the strongest independent 
prognostic factor. Patients with a GS of 5–7 
(3 + 4) had a very low risk for progression. 
Patients with a GS of 4 + 3 had a moderate 
risk, which was similar to that of patients with 
GS 8. The risk for progression in patients with 
a GS of 9–10 was very high, and also 
significantly higher than in patients with GS 
7 (4 + 3)–8. It has previously been shown that 
GS 4 + 3 cancers behave more aggressively 
than GS 3 + 4 cancers in surgically treated 
patients [37–39]. Here, our data suggest that 
GS 3 + 4 vs 4 + 3 is a critical prognostic 
threshold between very low and moderate risk 
in patients treated with ADT. Also, GS 9–10 
cancers behave clearly more aggressively than 
those of GS 8, and these cancers should not 
be grouped together.
Gleason score is assessed by a pathologist 
on the basis of glandular architecture. 
Reproducibility of GS is not optimal due to 
extreme variation of the architectural 
patterns and because the interobserver 
variability has been rather high [40,41]. The 
refinement of the Gleason grading system in 
needle biopsies by the ISUP [30] has proven to 
be valuable in identifying more patients with 
aggressive disease [42,43] and in improving 
interobserver agreement [44]. However, the 
comparison of the results of different studies 
over time has been difficult because of the 
changing definitions of GS [45]. Previous 
studies on radical prostatectomy specimens 
have suggested tumours with modified GS 3 + 
4 might behave in a similar way to GS 3 + 3 
tumours, whereas GS 4 + 3 tumours are more 
aggressive [46]. Refined guidelines of the ISUP 
consensus conference 2005 may have shifted 
the traditional low-grade vs high-grade 
threshold, but there has been a lack of studies 
showing this on core biopsy material [44]. 
The results on needle biopsies from the 
present study support earlier findings on 
prostatectomy specimens by demonstrating 
that patients with GS 4 + 3 have poorer 
prognosis than patients with GS 3 + 4.
The risk ratio for WHO grade was high in 
univariate analysis, but it did not reach a 
statistically independent prognostic value in 
the multivariate analysis. When a three-step 
FIG. 3. Kaplan–Meier progression-free survival curves according to PNI (A), WHO grade (B), Ki-67 (C), MCM7 
(D), and EZH2 (E). P values according to Mantel–Cox test are shown.
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classification system is in use, pathologists 
tend to classify most cases as intermediate. 
Here, over two-thirds of cases were 
considered as WHO grade II, which is a severe 
limitation of its usefulness for clinicians.
Pathological stage is the most important 
predictor of outcome and a golden standard 
in measuring local spread and tumour 
volume. In patients not treated with 
prostatectomy, there are several ways to 
estimate the pT-stage and/or tumour volume, 
including cT-stage, CPC [11,47], GPC [8] and 
TPC [12]. Indeed, all these variables show 
strong associations with each other. In the 
univariate analysis, CPC had the highest RR of 
the tumour volume estimates. Also, both GPC 
and TPC showed significant prognostic value. 
CPC, GPC and TPC provide important 
complementary data to the clinical T-stage. 
The reproducibility of percentile estimation of 
GPC and TPC should be optimized with the aid 
of digital image analysis in future.
Perineural invasion was found to be an 
independent prognostic marker in both 
multivariate analyses. Previously, the findings 
on the significance of PNI have been 
controversial. The presence of PNI in needle 
biopsies has shown independent predictive 
value of aggressive phenotype and Gleason 
upgrading in prostatectomy specimens 
[13,48]. However, PNI has lacked independent 
prognostic power in most studies on 
prostatectomy patients [8,13,49]. In one study 
on patients treated with external beam 
radiotherapy, PNI predicted biochemical 
progression [50]. The increasing diameter of 
the largest PNI has been associated with a 
higher rate of biochemical progression in 
surgically treated patients [51]. PNI is 
commonly seen in radical prostatectomy 
specimens close to the capsule or in 
extraprostatic tissue. Therefore we assumed 
that multiple PNI would correlate with the 
extent of capsular invasion. In the present 
study, not only the mere presence of PNI but 
also the number of perineurally invaded 
nerves was significantly associated with 
progression-free time. These data show 
that the presence of multiple PNI is an 
independent prognostic marker in endocrine-
treated patients, and it should be included in 
the pathology report on needle biopsies.
It was indicated more than a decade ago that 
cell proliferation activity is a prognostic 
marker in endocrine-treated prostate cancer 
[52]. Also, a high Ki-67 labelling index was 
shown to be an independent prognostic 
factor in some studies [53]. In the present 
study, Ki-67 was a statistically significant 
prognostic marker in univariate analysis but 
not an independent marker in multivariate 
analyses; however, patients with Ki-67 >10% 
were at a very high risk of progression 
(Fig. 3C). In patients with a GS of 7, 
reproducibility of the GS is critical. A Ki-67 
labelling index >10% was significantly 
associated with poor prognosis in patients 
with a GS of 7 and could be helpful in their 
risk assessment (Fig. 4B).
Over-expression of both MCM7 and EZH2 has 
been found in cancers with aggressive 
features, but it has not been thoroughly 
studied early in patients receiving primary 
ADT. Both biomarkers were significant 
prognostic markers in univariate analysis, but 
they lacked independent prognostic power in 
multivariate analysis. The RR values (95% CI) 
for the three biomarkers were 3.4 (2.1–5.5) for 
Ki-67, 2.4 (1.5–3.9) for MCM7, and 2.0 (1.2–
3.3) for EZH2. These values are similar to the 
currently used histopathological variables 
included in pretreatment nomograms. The 
intensity of immunostaining is variable, and 
often, the objective discrimination between 
positive and negative nuclei is difficult. 
Computer-based automated image analysis is 
a useful approach, as proved by the analysis 
of the immunostainings in the present study. 
Due to variables used in the programming, the 
FIG. 4. Kaplan–Meier progression-free survival curves in GS 7 cases according to scores 4 + 3 and 3 + 4 (A), 
and Ki-67% (threshold 10%) (B), as well as in all patients stratified for low- and high-risk groups according 
to the following criteria for high-risk group GS > 3 + 4 or PSA level > 20 ng/mL or cT-stage > 2 or PNI > 3 (C), 
GS > 7 or PSA level > 20 ng/mL or cT-stage > 2 or PNI > 3 (D), and GS > 8 or PSA level > 20 ng/mL or cT-stage 
> 2 or PNI > 3 (E). RR values and 95% CIs according to Cox univariate analysis and P values according to 
Mantel–Cox test are shown.
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results of automated segmentation are not 
strictly the same as manual counting, but they 
are very similar. The major advantage of using 
this method is high reproducibility in 
detecting immunostained nuclei and speed of 
counting hundreds of cells.
The prognosis of prostate cancer in elderly 
men is good, in general, and cancer-specific 
mortality is significantly lower than deaths 
due to other reasons [54]. Because of that, we 
were unable to use cancer-specific death as 
the primary endpoint. However, PSA 
progression is believed to be a reliable 
surrogate marker of survival [28]. Another 
weakness of the present study is that, for 
large fraction of patients, bone scintigraphy 
was not performed, although the probability 
that these patients would have had bone 
metastases is very low [55]. The third 
weakness is related to needle biopsy material: 
the evaluation of the histopathological 
variables was based on the original serial-cut 
H&E slides with more complete cores, 
whereas immunohistochemistry was 
performed on sections from the block 
remnants, which could cause a bias under-
estimating the significance of the 
immunostainings. The original slides or 
paraffin blocks were not available from 45 
patients. As there were no statistical 
differences between the missed cases and the 
studied cases, we consider the material to be 
unbiased.
In conclusion, there are many significant 
prognostic factors in prostate cancer. There 
were four common independent factors in 
both multivariate analyses: GS, PSA level, PNI 
and cT-stage. Combination of these variables 
provides a strong prognosticator with a RR of 
more than 10. As all of the studied variables 
were associated with each other, the 
independent prognostic value of the 
biomarkers is dependent on the accuracy of 
the subjective GS. Although GS was superior 
to the studied biomarkers in multivariate 
analysis, its reproducibility is not optimal, and 
the scores are variable between individual 
pathologists and clinics. We believe the use of 
Ki-67 with a threshold value of 10% in clinical 
routine could support clinical decision-
making. It could be especially helpful in 
determining the risk and choice of treatment 
for patients with a GS of 7.
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Abstract  
Background 
Prostatic needle biopsies are individually paraffin-embedded in 57 % of the European pathology 
laboratories, whereas the rest of laboratories embed multiple (2 - 6) biopsies per one paraffin-block. 
Differences in the processing method can have a far-reaching effect, because reporting of the 
Gleason score (GS) is different for individually embedded and pooled biopsies, and GS is one of the 
most important factors when selecting treatment for patients. Also, Gleason scoring has experienced 
several modifications during the past decade. So far, only one study has compared the prognostic 
abilities of worst (WGS) and overall (OGS) modified Gleason scores after the ISUP 2005 
conference.  
Methods 
The study material consisted of needle biopsies from 236 prostate cancer patients that were 
endocrine-treated in 1999-2003. Biopsies from left side and right side were embedded separately. 
Haematoxylin-eosin-stained slides were scanned and analyzed on web-based virtual microscopy. 
Worst and overall Gleason scores were assessed according to the modified Gleason score schema 
after analyzing each biopsy separately. The compound Gleason scores (CGS) were obtained from 
the original pathology reports. The prognostic ability of the three scoring methods to predict 
biochemical progression was compared with Kaplan-Meier survival analysis and univariate and 
multivariate Cox regression analyses. 
Results 
The median follow-up time of the patients was 64.5 months (range 0-118). The modified GS criteria 
led to upgrading of the Gleason sums compared to the original CGS from the pathology reports 
1999-2003 (mean 7.0 for CGS, 7.5 for OGS, 7.6 for WGS). In 43 cases WGS was > OGS. In a 
univariate analysis the relative risks were 2.1 (95%-confidence interval 1.8-2.4) for CGS, 2.5 (2.1-
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2.8) for OGS, and 2.6 (2.2-2.9) for WGS. In a multivariate analysis, OGS was the only independent 
prognostic factor. 
Conclusions 
All of the three Gleason scoring methods are strong predictors of biochemical recurrence. The use 
of modified Gleason scoring leads to upgrading of GS, but also improves the prognostic value of 
the scoring. No significant prognostic differences between OGS and WGS could be shown, which 
may relate to the apparent narrowing of the GS scale from 2-10 to 5-10 due to the recent 
modifications. 
 
Background  
 
Grading of prostatic needle biopsies has experienced several refinements in the last decade. First, 
Epstein suggested that a diagnosis of Gleason score (GS) 2+2=4 cancer should not be made on the 
needle biopsies, because subsequent radical specimen showed upgrading in virtually all cases [1]. 
Next, worst Gleason score (WGS) was shown superior to overall Gleason score (OGS) in predicting 
the final GS of the radical specimen, yielding fewer cases of unwanted upgrading events [2]. Third 
major adaptation was made in the consensus conference of International Society of Urological 
Pathology 2005, leading to a refinement called modified GS [3]. In that, any aggressive cancer seen 
on the needle biopsies should be recorded and incorporated to the GS, even if present in small 
amount.  
Worst Gleason score (WGS) is recommended for individually processed biopsies by ISUP 2005 
consensus conference [3]. In the case of pooled biopsies, the exact number of biopsies is sometimes 
difficult to know due to tissue fragmentation and/or overlapping of the biopsies, and thus, WGS 
cannot be reliably assessed [3]. 
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According to a recent survey among European pathology laboratories, approximately one half of the 
participants use individually processed biopsies, while the others immerse multiple biopsies per 
formalin container without special identification tags (Lars Egevad, personal communication). 
Individually processed biopsies allow clinicians to localize the histopathological findings to the 
anatomic biopsy site. In addition, when the biopsy cores are individually embedded in paraffin 
blocks, a separate GS can be assessed for each biopsy, and the worst of them is usually reported to 
the clinicians to guide the treatment. Instead, the uropathologists did not reach consensus whether to 
use worst or overall GS in the case when multiple cancer-containing biopsies are pooled to one 
formalin container without identification tags [3]. 
A few studies comparing OGS and WGS have been published and only one of them after the ISUP 
conference [4]. In three studies WGS at any biopsy site was better than OGS at predicting the 
pathological T-stage and GS in radical prostatovesiculectomy specimens [2, 4, 5] whereas in one 
study, OGS performed better in predicting progression-free survival in patients treated with 
radiotherapy [6]. 
Our earlier study analyzing biopsies from endocrine-treated patients indicated that OGS was the 
strongest independent prognosticator of all histopathological parameters [7]. Gleason score 
assessment according to ISUP 2005, using the most aggressive pattern as a secondary Gleason 
grade even when it is present in only a small area, yielded the best prognostic classification using 
groupings <7(4+3), 7(4+3)-8, and 9-10. In the present study, we examined whether the WGS in a 
single biopsy core would improve prognostic accuracy when compared with OGS. We also 
evaluated the prognostic value of compound Gleason score from the original pathology reports 
before the ISUP 2005 era.  
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Methods 
 
Material 
The study was approved by the Ethical Committee of Tampere University Hospital (TAUH) and the 
National Authority for Medicolegal Affairs. From 1999 to 2003, 295 consecutive new prostate 
cancer patients, diagnosed from core biopsies, were primarily hormonally treated in the TAUH. 
Representative formalin-fixed, paraffin-embedded samples were available from 236 (80%) cases. 
Of these, clinical follow-up data were available for 233/236 (99%) cases. The end-point, 
biochemical progression, was defined as a ≥ 25% rise in PSA, with a PSA value ≥ 2.0 ng/ml above 
the nadir in two consecutive measurements, as recommended by The Prostate Cancer Clinical Trials 
Working Group (PCWG2) guidelines [8]. The median PSA value at the time of diagnosis was 15.5 
ng/ml (mean 144 ng/ml, S.D. 772). Tumors were organ-confined (clinical T1-2) in 126 patients and 
advanced (cT3-4) in 107 patients. Bone scintigraphy was done in all symptomatic patients and in 
asymptomatic patients when PSA was ≥20 ng/ml or they had aggressive (original compound GS 
>7) prostate cancer. Based on bone scintigraphy, metastasis was detected in 40 (17%) patients. The 
primary hormonal treatments were luteinizing-hormone releasing-hormone (LHRH) analog 
(n=169), surgical castration (n=43), antiandrogen bicalutamide (n=21), and maximal androgen 
blockade (n=3).  
 
Two slides from each patient were analyzed. The most representative hematoxylin and eosin 
(H&E)-stained slide, consisting of biopsies from the left or right lobe, was selected and scanned 
with Aperio ScanScope® XT (software version 9; Aperio Technologies, USA) and viewed in 
JPEG2000 format using JVSview virtual microscopy software (version 1.2) [9].  
 
The WGS and OGS were evaluated according to the recommendations of the International Society 
of Urological Pathologists 2005 [3]. The overall Gleason score was derived as a sum of the 
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predominant and the most aggressive (or secondary) patterns of all the biopsy cores, treated as one 
long core. The worst Gleason score in a single biopsy core was assessed in cases for which one 
biopsy contained a higher Gleason grade (e.g., 4+4 cancer) and other cores a lower grade (e.g. 3+4). 
In the cases in which all positive biopsy cores contained same Gleason grade (e.g., 3+3) or there 
was only one core positive for cancer, the WGS was equal to the OGS. A Gleason score of 7 was 
considered as two separate grades (e.g., the WGS could equal 4+3 and the OGS 3+4). The CGS was 
obtained from the original pathology reports, in which it was assessed as sum of the predominant 
and the second most common Gleason patterns based on the evaluation of needle biopsy specimens 
from both lobes. 
 
Statistical analysis 
The agreement between Gleason scoring methods was analyzed with the κ-coefficient method. A 
survival analysis with PSA progression as end-point was performed using the Kaplan–Meier 
method, and the statistical significance of survival differences between patient groups was 
determined with a Mantel-Cox test. The univariate and multivariate Cox regression analyses were 
performed to calculate the relative risk estimates (RR) and to evaluate the independence of the 
prognostic grading methods. 
 
Results 
 
Basic characteristics 
The median age of the patients was 73.8 years (range 52.7-88.8). The median PSA at the time of 
diagnosis was 15.7 ng/ml (range 2.4-10750.0 ng/ml). The median follow-up time was 64.5 months 
(range 0-118). The average number of core biopsies from one lobe was 4.5 (median 4, range 1-9), 
and the average number of positive biopsy sites was 3.1 (median 3, range 1-7).  
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Needle biopsy findings 
The number of cases with multiple positive biopsy sites was 191/236 (80.9 %) and WGS was higher 
than OGS in 43/236 (18.2 %) cases. In general, the modified GS system yielded to higher Gleason 
scores. The average GS was 7.6 (median 8, 95%-confidence interval 5.0-10.3) for WGS, 7.5 (7.0, 
5.0-10.0) for OGS, and 7.0 (7, 4.5-9.6) for CGS. The distribution of Gleason scores according to 
grading method is shown in Figure 1. The number of cases with OGS=7 was 65. In 14 (22 %) cases 
of them there was at least one positive biopsy core containing higher-grade cancer (WGS 4+4=8). 
In 12 (31 %) of 39 cases with OGS 3+4=7, a positive biopsy core with the highest score showed 
WGS 4+3. Overall GS=9 was encountered in 52 cases of which the biopsy core with highest GS 
showed WGS=10 in 10 (19 %) cases. In three cases the difference between WGS and OGS was 2; 
in all of them OGS=8 (3+5 or 5+3) and WGS=10 (5+5).  
 
Statistical analyses 
The agreement between WGS and OGS was high (κ-coefficient=0.82). A significantly lower 
concordance was found between WGS and CGS (κ=0.48) and OGS and CGS (κ=0.44). All Gleason 
scoring methods provided prognostically highly significant information (Fig 2A, 2B, 2C, 2D, 2E, 
and 2F).  
The univariate analyses of OGS and WGS yielded similar relative risks (Fig 2). Re-classification of 
the Gleason score groups to <7(4+3), 7(4+3)-8, 9-10 improved slightly prognostic value of the 
scoring. In the multivariate analysis of the six different Gleason grading methods, OGS reclassified 
as <7(4+3), 7(4+3)-8, 9-10 was the strongest (and only) independent prognostic factor (RR 2.6, 
95% confidence interval 2.0-3.5).  
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Discussion 
 
The refinements of the ISUP 2005 consensus conference on Gleason scoring of needle biopsies has 
generally yielded better prognostic accuracy [10]. Our results indicate that modified Gleason scores 
according to the ISUP 2005 system are higher than compound GS´s from 1999-2003, and this 
upgrading is associated with improved prognostic accuracy. Moreover, the results suggest, that 
OGS may be a slightly stronger or at least equally adequate predictor of PSA progression than 
WGS, when assessed from pooled biopsies. 
 
A major implication of the revised 2005 ISUP guidelines has been the integration of the most 
aggressive pattern into Gleason scores as a secondary pattern, even when the pattern is limited to a 
small area. Due to this, a fraction of cancers previously graded as GS 3+3=6 would nowadays end 
up with GS 3+4=7. It has been suggested that changing definitions shift the cut-off between low-
grade and high grade cancers from 3+4 to 4+3 [11, 12]. The results of the present study are 
consistent with that.  
 
According to the 2005 ISUP consensus conference, the highest (worst) GS should not be assessed 
from biopsies immersed in the same formalin container (“pooled biopsies”) due to tissue 
fragmentation [3]. When all six biopsies from one lobe are formalin-fixed in the same container, 
they may become fragmented or overlap when embedded, disturbing the attempt to assess the WGS 
of the individual needle biopsies. On the other hand, WGS was recently shown to be a better 
predictor of the histopathological findings from subsequent radical prostatectomy specimens [4]. In 
our study, the WGS was assessed from the needle biopsies of one prostate lobe embedded in one 
paraffin block. Because of this, it is possible that our WGS results were biased by tissue 
fragmentation. However, in the majority of the cases (n=193/236, 82%), the WGS was equal to the 
OGS. If there was a bias due to fragmentation, we should expect more cases with WGS > OGS.  
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A major problem when multiple biopsies are stored in one container is that the exact locus 
information of the biopsies is lost unless site identifiers are used. The locus information is essential 
when considering targeted brachytherapy or cryotherapy in focal carcinomas. Moreover, the 
anatomic localization of carcinoma foci is useful when planning nerve-sparing radical 
prostatectomy and to avoid side effects from external-beam radiotherapy. The problems associated 
with placing multiple biopsies in one container can be overcome by immersing one core biopsy per 
formalin-container, which is quite laborious for all the participants: the urologist, laboratory 
technicians, and pathologist. Two major advantages of embedding multiple needle biopsy cores in 
one paraffin block are the reduced workload and the ability to analyze immunohistochemical 
stainings from all the biopsies at once, when deemed necessary.  
 
There are a few limitations in the present study. First, although PSA progression works as a 
surrogate end-point for progressive prostate cancer, it does not necessarily correlate specifically 
with cancer or overall survival. Due to the small number of deaths in our series, we cannot conclude 
that OGS was a better prognostic factor in terms of death as a hard end-point. To address this 
question, a longer follow-up is needed. Second, CGS was not re-evaluated in the present study; 
instead it was obtained from the original pathology reports, which limits the value of this 
comparison. Third, the number of cases in which WGS > OGS was rather low (n=43). 
 
Conclusions 
Overall and worst Gleason scores provide comparable prognostic information. We conclude that 
clinicopathological practice using one container per lobe (six biopsies) and yielding an overall 
Gleason score is a straightforward and cost-effective procedure that correlates well to prognosis in 
hormone-treated patients. Therefore, the use of individually embedded biopsies should be dictated 
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by the need for anatomic site information and weighed against the increased workload for the 
pathology laboratory 
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Figure legends: 
 
Figure 1 – Gleason score distributions 
Distribution of Gleason scores (GS) according to the grading method. The number of cases with GS 
7 is overemphasized by using compound GS, before the revised guidelines by ISUP 2005 were in 
routine use. Major changes between overall Gleason score (OGS) and worst Gleason score (WGS) 
are noted in shift from OGS 7 to WGS 8 and from OGS 9 to WGS 10. 
 
 
Figure 2- Survival curves 
Kaplan–Meier progression-free survival curves according to compound Gleason score (CGS) <7, 7, 
>7 from both lobes (A), CGS <7(4+3), 7(4+3)-8, 9-10 from both lobes (B), overall Gleason score 
(OGS) <7, 7, >7 from the most representative lobe (C), OGS <7(4+3), 7(4+3)-8, 9-10 from the most 
representative lobe (D), the worst Gleason score (WGS) <7, 7, >7 in a single biopsy from the most 
representative lobe (E), the WGS <7(4+3), 7(4+3)-8, 9-10 in a single biopsy from the most 
representative lobe (F). Relative risks (RR) with 95%-confidence intervals (95%-CI) according to 
Cox univariate analysis as well as p-values according to Mantel-Cox tests are shown.  
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Figure 1. 
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Figure 2. 
 
 
 
